Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 150
You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::index() - APP/Controller/ArtileDetailController.php, line 150
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 97
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98
Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 151
You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::index() - APP/Controller/ArtileDetailController.php, line 151
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 97
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98
Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
if (Configure::read('debug')) {
trigger_error($message, E_USER_WARNING);
} else {
$response = object(Cake\Http\Response) {
'status' => (int) 200,
'contentType' => 'text/html',
'headers' => [
'Content-Type' => [
[maximum depth reached]
]
],
'file' => null,
'fileRange' => [],
'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
'cacheDirectives' => [],
'body' => '<!DOCTYPE html>
<!--[if lt IE 7 ]>
<html class="ie ie6" lang='en'> <![endif]-->
<!--[if IE 7 ]>
<html class="ie ie7" lang='en'> <![endif]-->
<!--[if IE 8 ]>
<html class="ie ie8" lang='en'> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!-->
<html lang='en'>
<!--<![endif]-->
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<title>
LATEST NEWS UPDATES | Western warnings-R Ramachandran </title>
<meta name="description" content="
India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines.
AS was only to be expected, the two landmark decisions made by the Indian patent office in recent..."/>
<meta name="keywords" content="Health,patents,medicines"/>
<meta name="news_keywords" content="Health,patents,medicines">
<link rel="alternate" type="application/rss+xml" title="ROR" href="/ror.xml"/>
<link rel="alternate" type="application/rss+xml" title="RSS 2.0" href="/feeds/"/>
<link rel="stylesheet" href="/css/bootstrap.min.css?1697864993"/> <link rel="stylesheet" href="/css/style.css?v=1.1.2"/> <link rel="stylesheet" href="/css/style-inner.css?1577045210"/> <link rel="stylesheet" id="Oswald-css"
href="https://fonts.googleapis.com/css?family=Oswald%3Aregular%2C700&ver=3.8.1" type="text/css"
media="all">
<link rel="stylesheet" href="/css/jquery.modal.min.css?1578285302"/> <script src="/js/jquery-1.10.2.js?1575549704"></script> <script src="/js/jquery-migrate.min.js?1575549704"></script> <link rel="shortcut icon" href="/favicon.ico" title="Favicon">
<link rel="stylesheet" href="/css/jquery-ui.css?1580720609"/> <script src="/js/jquery-ui.js?1575549704"></script> <link rel="preload" as="style" href="https://www.im4change.org/css/custom.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel="preload" as="style" href="https://www.im4change.org/css/jquery.modal.min.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel="preload" as="style" href="https://www.im4change.org/css/jquery-ui.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel="preload" as="style" href="https://www.im4change.org/css/li-scroller.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<!-- <link rel="preload" as="style" href="https://www.im4change.org/css/style.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous"> -->
<link rel="preload" as="style" href="https://www.im4change.org/css/style-inner.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel='dns-prefetch' href="//im4change.org/css/custom.css" crossorigin >
<link rel="preload" as="script" href="https://www.im4change.org/js/bootstrap.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery.li-scroller.1.0.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery.modal.min.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery.ui.totop.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery-1.10.2.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery-migrate.min.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery-ui.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/setting.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/tie-scripts.js">
<!--[if IE]>
<script type="text/javascript">jQuery(document).ready(function () {
jQuery(".menu-item").has("ul").children("a").attr("aria-haspopup", "true");
});</script>
<![endif]-->
<!--[if lt IE 9]>
<script src="/js/html5.js"></script>
<script src="/js/selectivizr-min.js"></script>
<![endif]-->
<!--[if IE 8]>
<link rel="stylesheet" type="text/css" media="all" href="/css/ie8.css"/>
<![endif]-->
<meta property="og:title" content="LATEST NEWS UPDATES | Western warnings-R Ramachandran" />
<meta property="og:url" content="https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575.html" />
<meta property="og:type" content="article" />
<meta property="og:description" content="
India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines.
AS was only to be expected, the two landmark decisions made by the Indian patent office in recent..." />
<meta property="og:image" content="" />
<meta property="fb:app_id" content="0" />
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no">
<link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://im4change.in/images/apple1.png">
<link rel="apple-touch-icon-precomposed" sizes="120x120" href="https://im4change.in/images/apple2.png">
<link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://im4change.in/images/apple3.png">
<link rel="apple-touch-icon-precomposed" href="https://im4change.in/images/apple4.png">
<style>
.gsc-results-wrapper-overlay{
top: 38% !important;
height: 50% !important;
}
.gsc-search-button-v2{
border-color: #035588 !important;
background-color: #035588 !important;
}
.gsib_a{
height: 30px !important;
padding: 2px 8px 1px 6px !important;
}
.gsc-search-button-v2{
height: 41px !important;
}
input.gsc-input{
background: none !important;
}
@media only screen and (max-width: 600px) {
.gsc-results-wrapper-overlay{
top: 11% !important;
width: 87% !important;
left: 9% !important;
height: 43% !important;
}
.gsc-search-button-v2{
padding: 10px 10px !important;
}
.gsc-input-box{
height: 28px !important;
}
/* .gsib_a {
padding: 0px 9px 4px 9px !important;
}*/
}
@media only screen and (min-width: 1200px) and (max-width: 1920px) {
table.gsc-search-box{
width: 15% !important;
float: right !important;
margin-top: -118px !important;
}
.gsc-search-button-v2 {
padding: 6px !important;
}
}
</style>
<script>
$(function () {
$("#accordion").accordion({
event: "click hoverintent"
});
});
/*
* hoverIntent | Copyright 2011 Brian Cherne
* http://cherne.net/brian/resources/jquery.hoverIntent.html
* modified by the jQuery UI team
*/
$.event.special.hoverintent = {
setup: function () {
$(this).bind("mouseover", jQuery.event.special.hoverintent.handler);
},
teardown: function () {
$(this).unbind("mouseover", jQuery.event.special.hoverintent.handler);
},
handler: function (event) {
var currentX, currentY, timeout,
args = arguments,
target = $(event.target),
previousX = event.pageX,
previousY = event.pageY;
function track(event) {
currentX = event.pageX;
currentY = event.pageY;
}
;
function clear() {
target
.unbind("mousemove", track)
.unbind("mouseout", clear);
clearTimeout(timeout);
}
function handler() {
var prop,
orig = event;
if ((Math.abs(previousX - currentX) +
Math.abs(previousY - currentY)) < 7) {
clear();
event = $.Event("hoverintent");
for (prop in orig) {
if (!(prop in event)) {
event[prop] = orig[prop];
}
}
// Prevent accessing the original event since the new event
// is fired asynchronously and the old event is no longer
// usable (#6028)
delete event.originalEvent;
target.trigger(event);
} else {
previousX = currentX;
previousY = currentY;
timeout = setTimeout(handler, 100);
}
}
timeout = setTimeout(handler, 100);
target.bind({
mousemove: track,
mouseout: clear
});
}
};
</script>
<script type="text/javascript">
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-472075-3']);
_gaq.push(['_trackPageview']);
(function () {
var ga = document.createElement('script');
ga.type = 'text/javascript';
ga.async = true;
ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
var s = document.getElementsByTagName('script')[0];
s.parentNode.insertBefore(ga, s);
})();
</script>
<link rel="stylesheet" href="/css/custom.css?v=1.16"/> <script src="/js/jquery.ui.totop.js?1575549704"></script> <script src="/js/setting.js?1575549704"></script> <link rel="manifest" href="/manifest.json">
<meta name="theme-color" content="#616163" />
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-status-bar-style" content="black">
<meta name="apple-mobile-web-app-title" content="im4change">
<link rel="apple-touch-icon" href="/icons/logo-192x192.png">
</head>
<body id="top" class="home inner blog">
<div class="background-cover"></div>
<div class="wrapper animated">
<header id="theme-header" class="header_inner" style="position: relative;">
<div class="logo inner_logo" style="left:20px !important">
<a title="Home" href="https://im4change.in/">
<img src="https://im4change.in/images/logo2.jpg?1582080632" class="logo_image" alt="im4change"/> </a>
</div>
<div class="langhindi" style="color: #000;display:none;"
href="https://im4change.in/">
<a class="more-link" href="https://im4change.in/">Home</a>
<a href="https://im4change.in/hindi/" class="langbutton ">हिन्दी</a>
</div>
<nav class="fade-in animated2" id="main-nav">
<div class="container">
<div class="main-menu">
<ul class="menu" id="menu-main">
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children"
style="left: -40px;"><a
target="_blank" href="https://im4change.in/">Home</a>
</li>
<li class="menu-item mega-menu menu-item-type-taxonomy mega-menu menu-item-object-category mega-menu menu-item-has-children parent-list"
style=" margin-left: -40px;"><a href="#">KNOWLEDGE GATEWAY <span class="sub-indicator"></span>
</a>
<div class="mega-menu-block background_menu" style="padding-top:25px;">
<div class="container">
<div class="mega-menu-content">
<div class="mega-menu-item">
<h3><b>Farm Crisis</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/farmers039-suicides-14.html"
class="left postionrel">Farm Suicides </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/unemployment-30.html"
class="left postionrel">Unemployment </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/rural-distress-70.html"
class="left postionrel">Rural distress </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/migration-34.html"
class="left postionrel">Migration </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/key-facts-72.html"
class="left postionrel">Key Facts </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/debt-trap-15.html"
class="left postionrel">Debt Trap </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Empowerment</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/union-budget-73.html"
class="left postionrel">Union Budget And Other Economic Policies </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/forest-and-tribal-rights-61.html"
class="left postionrel">Forest and Tribal Rights </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-education-60.html"
class="left postionrel">Right to Education </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-food-59.html"
class="left postionrel">Right to Food </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/displacement-3279.html"
class="left postionrel">Displacement </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-work-mg-nrega-39.html"
class="left postionrel">Right to Work (MG-NREGA) </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/gender-3280.html"
class="left postionrel">GENDER </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-information-58.html"
class="left postionrel">Right to Information </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/social-audit-48.html"
class="left postionrel">Social Audit </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Hunger / HDI</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/poverty-and-inequality-20499.html"
class="left postionrel">Poverty and inequality </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/malnutrition-41.html"
class="left postionrel">Malnutrition </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/public-health-51.html"
class="left postionrel">Public Health </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/education-50.html"
class="left postionrel">Education </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/hunger-overview-40.html"
class="left postionrel">Hunger Overview </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/hdi-overview-45.html"
class="left postionrel">HDI Overview </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/pds-ration-food-security-42.html"
class="left postionrel">PDS/ Ration/ Food Security </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/sdgs-113.html"
class="left postionrel">SDGs </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/mid-day-meal-scheme-mdms-53.html"
class="left postionrel">Mid Day Meal Scheme (MDMS) </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Environment</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/environment/time-bomb-ticking-52.html"
class="left postionrel">Time Bomb Ticking </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/environment/water-and-sanitation-55.html"
class="left postionrel">Water and Sanitation </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/environment/impact-on-agriculture-54.html"
class="left postionrel">Impact on Agriculture </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Law & Justice</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/social-justice-20500.html"
class="left postionrel">Social Justice </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/access-to-justice-47.html"
class="left postionrel">Access to Justice </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/human-rights-56.html"
class="left postionrel">Human Rights </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/corruption-35.html"
class="left postionrel">Corruption </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/general-insecurity-46.html"
class="left postionrel">General Insecurity </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/disaster-relief-49.html"
class="left postionrel">Disaster & Relief </a>
</p>
</div>
</div>
</div>
</div>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page "><a target="_blank" href="https://im4change.in/nceus_reports.php">NCEUS reports</a>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children parent-list ">
<a target="_blank" href="https://im4change.in/about-us-9.html">About Us <span
class="sub-indicator"></span></a>
<ul class="sub-menu aboutmenu">
<li class="menu-item menu-item-type-post_type menu-item-object-page"><a
target="_blank" href="https://im4change.in/objectives-8.html">Objectives</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page"><a
target="_blank" href="https://im4change.in/contactus.php">Contact
Us</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page"><a
target="_blank" href="https://im4change.in/about-us-9.html">About
Us</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children ">
<a target="_blank" href="https://im4change.in/fellowships.php" title="Fellowships">Fellowships</a>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children "><a
target="_blank" href="https://im4change.in/media-workshops.php">Workshops</a>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children "><a
target="_blank" href="https://im4change.in/research.php">Research</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children "><a
target="_blank" href="https://im4change.in/links-64">Partners</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children"
id="menu-item-539"><a target="_blank" href="https://im4change.in/hindi/"
class="langbutton langlinkfont17">हिन्दी</a></li>
</ul>
</div> </div>
<!-- <div style="float: right;">
<script async src="https://cse.google.com/cse.js?cx=18b4f2e0f11bed3dd"></script>
<div class="gcse-search"></div>
</div> -->
<div class="search-block" style=" margin-left: 8px; margin-right: 7px;">
<form method="get" id="searchform" name="searchform"
action="https://im4change.in/search"
onsubmit="return searchvalidate();">
<button class="search-button" type="submit" value="Search"></button>
<input type="text" id="s" name="qryStr" value=""
onfocus="if (this.value == 'Search...') {this.value = '';}"
onblur="if (this.value == '') {this.value = 'Search...';}">
</form>
</div>
</nav>
</header>
<div class="container">
<div id="main-content" class=" main1 container fade-in animated3 sidebar-narrow-left">
<div class="content-wrap">
<div class="content" style="width: 900px;min-height: 500px;">
<section class="cat-box recent-box innerCatRecent">
<h1 class="cat-box-title">Western warnings-R Ramachandran</h1>
<a href="JavaScript:void(0);" onclick="return shareArticle(14451);">
<img src="https://im4change.in/images/email.png?1582080630" border="0" width="24" align="right" alt="Share this article"/> </a>
<a href="https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575/print"
rel="nofollow">
<img src="https://im4change.in/images/icon-print.png?1582080630" border="0" width="24" align="right" alt="Share this article"/>
</a>
</section>
<section class="recent-box innerCatRecent">
<small class="pb-1"><span class="dateIcn">
<img src="https://im4change.in/images/published.svg?1582080666" alt="published"/>
Published on</span><span class="text-date"> Apr 20, 2012</span>
<span
class="dateIcn">
<img src="https://im4change.in/images/modified.svg?1582080666" alt="modified"/> Modified on </span><span class="text-date"> Apr 20, 2012</span>
</small>
</section>
<div class="clear"></div>
<div style="padding-top: 10px;">
<div class="innerLineHeight">
<div class="middleContent innerInput latest-news-updates">
<table>
<tr>
<td>
<div>
<br /><div align="justify"><em>India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines. <br /></em><br />AS was only to be expected, the two landmark decisions made by the Indian patent office in recent times concerning pharmaceutical patent cases have not gone down well with the multinational drug industry. First, there was the rejection in 2006 of the patent application by the Swiss multinational Novartis for imatinib mesylate (sold under the brand name of Glivec, or Gleevec), its incrementally modified drug for leukaemia, or blood cancer. Then, on March 12, 2012, the Indian generic drug company Natco Pharma Ltd was granted a manufacturing licence to produce a generic version of the patented liver and kidney cancer drug sorafenib tosylate of the German multinational company (MNC) Bayer (brand name Nexavar) through the first-ever invocation of the compulsory licence (CL) provision in the Indian Patents Act, 1970 (as amended in 2005). The CL was granted to ensure affordability of the drug to Indian cancer patients. Natco will now produce the drug at a price that will be 97 per cent lower than Bayer's even after paying 6 per cent royalty on net sales to Bayer.<br /><br />Bayer will most likely appeal against the order. Novartis challenged the patent office's rejection of its patent application first at the Intellectual Property Appellate Board (IPAB) and subsequently in the Madras High Court. Both upheld the Patent Controller's decision and rejected Novartis' appeals against the Indian government. Now the company has appealed to the Supreme Court. The first hearing is slated for July 10. These two cases have demonstrated how flexibilities available in the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement (for patent protection) of the World Trade Organisation (WTO) can be successfully used to serve public health interests in developing countries over the interests of the private monopoly of profit-driven drug MNCs. The flexibilities in the TRIPS Agreement allow governments to decide what type of “innovation” is patentable. The criteria of “novelty”, “inventive step”, and “industrial applicability” are not defined in the agreement and are left for individual governments to determine within existing national legislation and circumstances. These are also, therefore, test cases for the Indian judiciary, and if these orders can be sustained in the face of imminent legal battles, they will serve as important precedents for exploiting the full power of the Indian Patents Act, while conforming to the WTO's intellectual property rights (IPR) regime, to ensure the Indian public access to health care it can afford.<br /><br />Drug majors around the world, American companies in particular, which have, of course, been watching the Novartis case anxiously for the past five years, have been further jolted by the latest decision on Nexavar. The president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), John Castellani, issued the following statement immediately after India granted the CL for the indigenous production of Nexavar's generic version:<br /><br />“While India has not routinely issued CLs, PhRMA believes it is not an appropriate tool even if granting CLs may be a legal option.… Legitimate health emergencies that require making exceptions to IPRs can, and should, be accommodated under the international framework, but only after exhausting all other efforts and under extraordinary circumstances…. [O]ne aspect that is particularly troublesome is the contention that ‘working' a patent requires a company to manufacture within India. It is our firm belief that this is fully at odds with India's TRIPS commitments (as well as broader WTO obligations), and distorts what was intended as a public health exception into an industrial policy…. CLs cannot solve India's larger problems regarding access to medicines and health care.”<br /><br />The PhRMA's contentions are patently wrong as the decision is in full compliance with the Doha “Declaration on the TRIPS Agreement and Public Health” of November 2001 and Article 31 of TRIPS. But the protest was conveyed more brazenly to the Indian government when the visiting United States Commerce Secretary, John Bryson, raised the issue of India granting a CL to Natco in his meeting with Commerce and Industry Minister Anand Sharma on March 25. Bryson apparently said that any dilution of the international patent regime was a cause for deep concern for the U.S. This was clearly an unwarranted remark on the part of the U.S. official because if there was any perceived violation of TRIPS, the correct forum for the U.S. to address the issue was the WTO.<br /><br />The U.S. has instituted an internal mechanism under its trade policy to deal with what it perceives as trade barriers in its trading-partner countries on the basis of an annual assessment in what is called the “Special 301 Report” by the office of the U.S. Trade Representative (USTR). India has consistently been placed in the “Priority Watch List” of the report. Following the court's rejection of Novartis' appeal in 2009, the 2010 report included a response of the USTR to the Indian decision.<br /><br />The report said: “The United States continues to urge India to improve its IPR regime by providing stronger protection for patents. One concern in this regard is a provision in India's Patent Law that prohibits patents on certain chemical forms absent a showing of increased efficacy. While the full import of this provision remains unclear, it appears to limit the patentability of potentially beneficial innovations, such as temperature-stable forms of a drug or new means of drug delivery” (emphasis added, throughout).<br /><br />The wording clearly reflects the U.S.' objection to the Indian patent office not granting a new patent for a new chemical form of a patented drug that the manufacturer claims had increased bioabsorption but for which there was no proven increased therapeutic efficacy. The 2011 report, too, essentially repeated the same objection to the restricted scope of patentability of drugs under the Patents Act. The administration's objection to the Bayer-Nexavar case is bound to be reflected in the 2012 report, given that the PhRMA has already voiced its protest. Drugs are big business around the world for the U.S. industry, and the PhRMA, which acts as the prime lobby group for the U.S. drug industry, naturally has a major influence on the contents of the Special 301 Report.<br /><br />In its submission to the USTR on the 2012 Special 301 Report, the PhRMA said the following with regard to the patentability criteria exercised by the Indian patent office in the Novartis case: “Some of the standards for patentability in India are not transparent and are inconsistent with the TRIPS Agreement. For example, Section 3(d) of the [Indian] Patents Act… creates additional hurdles to the grant of certain chemical compound patents, and appears to be applied only to pharmaceuticals. Under this provision, salts, esters, ethers, polymorphs, and other derivatives of known substances are presumed to be the same substance as the original chemical and thus not patentable, unless it can be shown that they differ significantly in properties with regard to efficacy. These additional requirements for patentability beyond novelty, commercial applicability and non-obviousness are inconsistent with the TRIPS Agreement.... Article 27 of the TRIPS Agreement provides a non-extendable list of the types of subject matter that can be excluded from patent coverage. This list does not include ‘new forms of known substances lacking enhanced efficacy', as excluded by Section 3(d) of the Indian law.” This argument is misplaced because the rejection is on the grounds of the new drug not meeting the basic criterion of patentability, which is novelty, meaning that it should be a new compound and should involve an inventive step. Novartis was seeking a patent for just the beta crystalline variant of a patented amorphous molecule, claiming merely better bioavailability. Such an incremental modification is not something that involves inventiveness, the court contended.<br /><br />On the issue of CLs, which is another key issue of concern to the PhRMA, its submission, made in February, a month before the decision on the Bayer case was pronounced, stated: “Domestic companies have started filing CL applications with the Indian patent office, apparently prompted in part by government statements suggesting that CLs may be a means for ensuring availability and affordability of drugs worldwide…. At a minimum, India should ensure that the CL provisions comply with TRIPS by... eliminating price as a trigger to CL.” (Section 84(1) (b) of the Indian Patents Act permits a CL if the patented invention is not available to the public at a “reasonably affordable price”.)<br /><br />This again is a misplaced objection because a country is free to decide on the reasons for granting a CL as is clear from the Doha Declaration, which says: “Each member has the right to grant compulsory licences and the freedom to determine the grounds upon which such licences are granted; Each member has the right to determine what constitutes a national emergency or other circumstances of extreme urgency, it being understood that public health crises, including those relating to HIV/AIDS, tuberculosis, malaria and other epidemics, can represent a national emergency or other circumstances of extreme urgency.” The patent office exercised the freedom of granting the CL to Natco on the issue of affordability, given that Natco's generic drug will cost Rs.8,800 a month as against Bayer's Rs.2.8 lakh a month and that cancer treatment is lifelong.<br /><br />Retaliation following the listing of a country on the watch list includes the U.S. initiating dispute settlement mechanisms at international trade forums such as the WTO, elimination of preferential tariff preferences under bilateral trade agreements, if any, and even unilateral trade sanctions against the named country. Bryson's remarks are perhaps a veiled threat of such action against India since there are many such pharmaceutical patent cases pending in Indian courts for which these cases could become precedents, affecting the potentially huge market of American MNCs.<br />Trade policy forum<br /><br />There exists a bilateral engagement between India and the U.S. under what is called the U.S.-India Trade Policy Forum (TPF) formed in 2005 alongside the various India-U.S. agreements that came into being, including the nuclear deal. The TPF has five focus groups: agriculture, investment, innovation and creativity (IPR), services, and tariff and non-tariff barriers. Under the TPF, a framework for cooperation and trade was signed two years ago.<br /><br />Although its proposed work plan does not specifically mention IPR, it does include a group focussing on tariff and non-tariff barriers, which is aimed at “promoting policies to expand market access, including adopting transparent, WTO-policies….” It is quite likely that this bilateral forum will begin to be used by the U.S. to bring on pressure on contentious issues concerning IPR.<br /><br />Interestingly, the scheduled meeting of the TPF has been postponed twice by the U.S. since October, the most recent being the meeting of the Commerce Minister with USTR Ron Kirk in January. According to media reports, this is because of insufficient progress achieved on the various issues, increasing market access to U.S. companies, in particular. Clearly, the U.S. will increase pressure on the IPR issue in the wake of the recent CL decision at the next meeting of the TPF, which has been pushed to mid-2012. The Indian government would do well to guard against that. Health-care activists and IPR experts have voiced similar concern over the proposed India-European Union (E.U.) Free Trade Agreement (FTA).<br /><br />According to reports, the 27-nation bloc has been pressing India to agree to an IPR regime over and above TRIPS. This demand is related to the area of pharmaceuticals, particularly after the Novartis decision, and this demand in all likelihood will become stronger now. Recently, however, Minister Anand Sharma assured a visiting UNAIDS (Joint United Nations Programme on HIV/AIDS) executive that India would reject efforts to include a “data exclusivity” clause in bilateral agreements and affirmed the Indian government's full commitment to ensure quality generic medicines through compulsory licensing and other TRIPS flexibilities. Notwithstanding this, in a recent article in The Guardian, Philippe Douste-Blazy, U.N. Special Adviser on Innovative Financing for Development, and Denis Broun, Executive Director of Unitaid, an international facility for the purchase of drugs for HIV/AIDS, malaria and tuberculosis hosted by the World Health Organisation in Geneva, wrote: “If stringent patent and border measures are agreed on at the E.U.-India FTA summit, patients in poor countries will no longer have access to cheap generic medicines; India's role as the ‘pharmacy of the South' could well come to an end.”<br /><br />The U.S. has already begun to exert such pressures and force countries in some other parts of the world into accepting IPR protection standards that are stronger than the TRIPS regime. Under the Trans-Pacific Partnership, a multilateral free trade agreement between the U.S. and the countries of the Asia-Pacific region that seeks to further liberalise these economies, the U.S. intends to broaden the scope of patentability by eroding the flexibility afforded by TRIPS by requesting TPP partner countries to pass new laws and rules that severely limit the ability of each country to define what is “patentable”. The nine countries currently negotiating the TPP are Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the U.S. and Vietnam. Japan and South Korea are intending to join the group shortly.<br /><br />A leaked draft of the chapter on IPR in a U.S.-negotiating TPP text, which reflects the U.S. position on this multilateral arrangement, indicates that the U.S. is demanding aggressive IPR provisions that go beyond what international trade law (under TRIPS) requires: “Each Party,” says the draft U.S. proposal, “ shall confirm that: patents shall be available for any new forms, uses, or methods of using a known product; and a new form, use, or method of using a known product may satisfy the criteria for patentability, even if such invention does not result in the enhancement of the known efficacy of that product.” This is the “patent evergreening” technique that Novartis tried to employ, which the Indian patent office rejected. Evergreening of a patent allows pharmaceutical companies to obtain or extend monopoly protection for old drugs simply by making minor modifications to existing formulae. The international organisation Medecins Sans Frontieres (Doctors Without Borders), which provides affordable health care around the world, points out: “Evergreening significantly delays the arrival of more affordable generic medicines into the market.” The TPP draft text further wants plants and animals and diagnostic, therapeutic and surgical methods for the treatment of humans or animals, which are explicitly ruled by TRIPS to be non-patentable, to be patentable.<br /><br />In addition, another leaked document pertaining to the TPP seeks to eliminate the process of pre-grant opposition to a patent application, which is an important tool to prevent patent applications based on weak or erroneous information. The U.S. proposal, if accepted, would allow opposition only after the patent is granted.<br /><br />Although this does not directly or immediately affect the Indian situation, it does portend ominous moves on this front by the U.S. on India as well. This is evident from the remarks Ron Kirk made recently: “U.S. involvement in the TPP is predicated on the expansion of the agreement to include more economies in the Asia-Pacific region…[and] should set the standard for 21st century trade agreements going forward.”<br /><br />It, therefore, stands to reason that the norms that emerge from the TPP negotiations will serve as the template for future U.S. trade agreements across the world. Using the leverage of the many countries in the TPP fold, and perhaps in other bilateral agreements, which accept this new enlarged premise for patentability, the WTO, too, eventually might come under pressure to change its rules of dispute settlement and arbitration. The implications of this are that IPR regimes, in particular the strict patentability criteria for drugs, of countries such as India, which have the responsibility of extending affordable health care to millions, will increasingly come under severe attack from the U.S. and the E.U., where nearly all the big drug multinationals operate and profit at the cost of the suffering poor of developing countries.</div>
</div>
</td>
</tr>
</table>
</div>
</div>
</div>
<div class="clear"></div>
<br><a href="http://www.frontlineonnet.com/stories/20120504290801800.htm" class="re" target="_blank">Frontline, Volume 29, Issue 08, 21 April-04 May, 2012, http://www.frontlineonnet.com/stories/20120504290801800.htm</a><div class="clear"></div>
<div style="padding-top: 18px;">
<p class="post-tag">Tagged with:
<a class="tagcloud5"
href="https://im4change.in/search?qryStr=Health"
title="Health">
Health </a>
<a class="tagcloud5"
href="https://im4change.in/search?qryStr=patents"
title="patents">
patents </a>
<a class="tagcloud5"
href="https://im4change.in/search?qryStr=medicines"
title="medicines">
medicines </a>
</p>
</div>
<div class="clear"></div>
<br><br>
<div class="widget-top">
<h4>Related Articles</h4>
<div class="stripe-line"></div>
</div>
<div class="widget-container">
<ul id="recentcomments">
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/fifth-report-from-gambia-implicates-indian-drug-maker-for-contaminated-syrups-banjot-kaur.html"
title="Fifth Report From Gambia Implicates Indian Drug Maker for Contaminated Syrups - Banjot Kaur">
Fifth Report From Gambia Implicates Indian Drug Maker for Contaminated Syrups - Banjot Kaur </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/india-may-have-seen-steepest-dip-in-multidimensional-poverty-among-110-nations-as-per-undp-data-nikhil-rampal.html"
title="India may have seen steepest dip in multidimensional poverty among 110 nations as per UNDP data - Nikhil Rampal">
India may have seen steepest dip in multidimensional poverty among 110 nations as per UNDP data - Nikhil Rampal </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/health-among-top-three-priorities-for-indian-voters-after-jobs-and-education-survey-shows-oliver-heath-jyoti-mishra-louise-tillin-sandhya-venkateswaran.html"
title="Health among top three priorities for Indian voters after jobs and education, survey shows - Oliver Heath, Jyoti Mishra, Louise Tillin & Sandhya Venkateswaran">
Health among top three priorities for Indian voters after jobs and education, survey shows - Oliver Heath, Jyoti Mishra, Louise Tillin & Sandhya Venkateswaran </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/prevalence-of-zero-food-among-infants-and-young-children-in-india-patterns-of-change-across-the-states-and-union-territories-of-india-1993-2021-the-lancet.html"
title="Prevalence of Zero-Food among infants and young children in India - The Lancet ">
Prevalence of Zero-Food among infants and young children in India - The Lancet </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/india-s-sustainability-goals-at-risk-because-of-extreme-heatwaves-carbon-copy.html"
title="India's Sustainability Goals at Risk Because of Extreme Heatwaves - Carbon Copy">
India's Sustainability Goals at Risk Because of Extreme Heatwaves - Carbon Copy </a>
</li>
</ul>
</div>
<div class="comment-respond" id="respond">
<a name="commentbox"> </a>
<h3 class="comment-reply-title" id="reply-title">Write Comments</h3>
<form method="post" accept-charset="utf-8" role="form" action="/latest-news-updates/western-warnings-r-ramachandran-14575.html"><div style="display:none;"><input type="hidden" name="_method" value="POST"/></div> <form class="comment-form" id="commentform" method="post" action="#commentbox" onSubmit="return validate()"
name="cmtform">
<input type="hidden" name="cmttype" value="articlecmt"/>
<input type="hidden" name="article_id" value="14451"/>
<p class="comment-notes">Your email address will not be published. Required fields are marked <span
class="required">*</span></p>
<p class="comment-form-author">
<label for="commenterName">Name</label>
<span class="required">*</span>
<input type="text" aria-required="true" size="30"
value=""
name="commenterName" id="commenterName" required="true">
</p>
<p class="comment-form-email">
<label for="commenterEmail">Email</label> <span class="required">*</span>
<input aria-required="true" size="30" name="commenterEmail" id="commenterEmail" type="email"
value=""
required="true">
</p>
<p class="comment-form-contact">
<label for="commenterPh">Contact No.</label>
<input type="text" size="30"
value=""
name="commenterPh" id="commenterPh">
</p>
<p class="comment-form-comment">
<label for="comment">Comment</label>
<textarea aria-required="true" required="true" rows="8" cols="45" name="comment"
id="comment"></textarea>
</p>
<p class="comment-form-comment">
<label for="comment">Type the characters you see in the image below <span class="required">*</span><br><img
class="captchaImg"
src="https://im4change.in/securimage_show_art.php?tk=462617871" alt="captcha"/>
</label>
</p>
<input type="text" name="vrcode" required="true"/>
<p class="form-submit" style="width: 200px;">
<input type="submit" value="Post Comment" id="submit" name="submit">
</p></form>
</div>
<style>
.ui-widget-content {
height: auto !important;
}
</style>
<div id="share-modal"></div>
<style>
.middleContent a{
background-color: rgba(108,172,228,.2);
}
.middleContent a:hover{
background-color: #418fde;
border-color: #418fde;
color: #000;
}
</style>
<script>
function shareArticle(article_id) {
var options = {
modal: true,
height: 'auto',
width: 600 + 'px'
};
$('#share-modal').html("");
$('#share-modal').load('https://im4change.in/share_article?article_id=' + article_id).dialog(options).dialog('open');
}
function postShare() {
var param = 'article_id=' + $("#article_id").val();
param = param + '&y_name=' + $("#y_name").val();
param = param + '&y_email=' + $("#y_email").val();
param = param + '&f_name=' + $("#f_name").val();
param = param + '&f_email=' + $("#f_email").val();
param = param + '&y_msg=' + $("#y_msg").val();
$.ajax({
type: "POST",
url: 'https://im4change.in/post_share_article',
data: param,
success: function (response) {
$('#share-modal').html("Thank You, Your message posted to ");
}
});
return false;
}
</script> </div>
</div>
<!-- Right Side Section Start -->
<!-- MAP Section START -->
<aside class="sidebar indexMarg">
<div class="ad-cell">
<a href="https://im4change.in/statemap.php" title="">
<img src="https://im4change.in/images/map_new_version.png?1582080666" alt="India State Map" class="indiamap" width="232" height="252"/> </a>
<div class="rightmapbox">
<div id="sideOne" class="docltitle"><a href="https://im4change.in/state-report/india/36" target="_blank">DOCUMENTS/
REPORTS</a></div>
<div id="sideTwo" class="statetitle"><a href="https://im4change.in/states.php"target="_blank">STATE DATA/
HDRs.</a></div>
</div>
<div class="widget widgePadTop"></div>
</div>
</aside>
<!-- MAP Section END -->
<aside class="sidebar sidePadbottom">
<div class="rightsmlbox1" >
<a href="https://im4change.in/knowledge_gateway" target="_blank" style="color: #035588;
font-size: 17px;">
KNOWLEDGE GATEWAY
</a>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title">
<a href="https://im4change.in/newsletter" target="_blank">
NEWSLETTER
</a>
</p>
</div>
</div>
<div class="rightsmlbox1" style="height: 325px;">
<div>
<p class="rightsmlbox1_title">
Interview with Prof. Ravi Srivastava
</p>
<p class="rightsmlbox1_title">
<a href="https://im4change.in/video/interview-with-prof-ravi-srivastava-on-current-economic-crisis">
<img width="250" height="200" src="/images/interview_video_home.jpg" alt="Interview with Prof. Ravi Srivastava"/>
</a>
<!--
<iframe width="250" height="200" src="https://www.youtube.com/embed/MmaTlntk-wc" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen=""></iframe>-->
</p>
<a href="https://im4change.in/videogallery" class="more-link CatArchalAnch1" target="_blank">
More videos
</a>
</div>
</div>
<div class="rightsmlbox1">
<div>
<!--div id="sstory" class="rightboxicons"></div--->
<p class="rightsmlbox1_title"><a href="https://im4change.in/list-success-stories" target="_blank">Success Stories</a></p>
</div>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title"><a
href="https://im4change.in/interviews" target="_blank">Interviews</a>
</p>
</div>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title"><a href="https://www.commoncause.in/page.php?id=10" >Donate</a></p>
</div>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title"><a
href="https://im4change.in/marquee"
class="isf_link more-link" title="India Focus?" style="border: 4px solid #fdd922;width: 90%;background-color: #fdd922;text-align: center;color: #000000;font-size:18px" target="_blank">India Focus</a></p> </div>
</div>
<div class="rightsmlbox1" style="height: 104px !important;">
<a href="https://im4change.in/quarterly_reports.php" target="_blank">
Quarterly Reports on Effect of Economic Slowdown on Employment in India (2008 - 2015)
</a>
</div>
<!-- <div class="rightsmlbox1">
<a href="https://play.google.com/store/apps/details?id=com.im4.im4change" target="_blank">
</a></div> -->
<!-- <section class="cat-box recent-box secMarg">
<h2 class="cat-box-title">Most Visited</h2>
</section> -->
<!-- accordion Starts here -->
<!-- <div id="accordion" class="accordMarg">
</div> -->
<!-- accordion ends here -->
<!-- Widget Tag Cloud Starts here -->
<div id="tag_cloud-2" class="widget widget_tag_cloud">
<section class="cat-box recent-box secMarg">
<h2 class="cat-box-title">MOST VISITED TAGS</h2>
</section>
<div class="widget-top wiPdTp">
<div class="stripe-line"></div>
</div>
<div class="widget-container">
<div class="tagcloud">
<a href="https://im4change.in/search?qryStr=Agriculture"
target="_blank" class="tag-link-4 font4">Agriculture</a>
<a href="https://im4change.in/search?qryStr=Food Security"
target="_blank" class="tag-link-4 font4">Food Security</a>
<a href="https://im4change.in/search?qryStr=Law and Justice"
target="_blank" class="tag-link-4 font4">Law and Justice</a>
<a href="https://im4change.in/search?qryStr=Health"
target="_blank" class="tag-link-4 font4">Health</a>
<a href="https://im4change.in/search?qryStr=Right to Food"
target="_blank" class="tag-link-4 font4">Right to Food</a>
<a href="https://im4change.in/search?qryStr=Corruption"
target="_blank" class="tag-link-4 font4">Corruption</a>
<a href="https://im4change.in/search?qryStr=farming"
target="_blank" class="tag-link-4 font4">farming</a>
<a href="https://im4change.in/search?qryStr=Environment"
target="_blank" class="tag-link-4 font4">Environment</a>
<a href="https://im4change.in/search?qryStr=Right to Information"
target="_blank" class="tag-link-4 font4">Right to Information</a>
<a href="https://im4change.in/search?qryStr=NREGS"
target="_blank" class="tag-link-4 font4">NREGS</a>
<a href="https://im4change.in/search?qryStr=Human Rights"
target="_blank" class="tag-link-4 font4">Human Rights</a>
<a href="https://im4change.in/search?qryStr=Governance"
target="_blank" class="tag-link-4 font4">Governance</a>
<a href="https://im4change.in/search?qryStr=PDS"
target="_blank" class="tag-link-4 font4">PDS</a>
<a href="https://im4change.in/search?qryStr=COVID-19"
target="_blank" class="tag-link-4 font4">COVID-19</a>
<a href="https://im4change.in/search?qryStr=Land Acquisition"
target="_blank" class="tag-link-4 font4">Land Acquisition</a>
<a href="https://im4change.in/search?qryStr=mgnrega"
target="_blank" class="tag-link-4 font4">mgnrega</a>
<a href="https://im4change.in/search?qryStr=Farmers"
target="_blank" class="tag-link-4 font4">Farmers</a>
<a href="https://im4change.in/search?qryStr=transparency"
target="_blank" class="tag-link-4 font4">transparency</a>
<a href="https://im4change.in/search?qryStr=Gender"
target="_blank" class="tag-link-4 font4">Gender</a>
<a href="https://im4change.in/search?qryStr=Poverty"
target="_blank" class="tag-link-4 font4">Poverty</a>
<a href="https://im4change.in/search?qryStr=Farm Laws" target="_blank" class="tag-link-4 font4">Farm Laws
</a>
<a href="https://im4change.in/search?qryStr=Citizenship Amendment Act" target="_blank" class="tag-link-4 font4">Citizenship Amendment Act
</a>
<a href="https://im4change.in/search?qryStr=CAA NPR NRIC" target="_blank" class="tag-link-4 font4">CAA NPR NRIC
</a>
<a href="https://im4change.in/search?qryStr=Job Losses" target="_blank" class="tag-link-4 font4">Job Losses
</a>
<a href="https://im4change.in/search?qryStr=Migrant Workers" target="_blank" class="tag-link-4 font4">Migrant Workers
</a>
<a href="https://im4change.in/search?qryStr=Unemployment" target="_blank" class="tag-link-4 font4">Unemployment
</a>
<a href="https://im4change.in/search?qryStr=PMGKAY" target="_blank" class="tag-link-4 font4">PMGKAY
</a>
<a href="https://im4change.in/search?qryStr=PM-KISAN" target="_blank" class="tag-link-4 font4">PM-KISAN
</a>
<a href="https://im4change.in/search?qryStr=PM-CARES" target="_blank" class="tag-link-4 font4">PM-CARES
</a>
<a href="https://im4change.in/search?qryStr=LFPR" target="_blank" class="tag-link-4 font4">LFPR
</a>
</div>
</div>
</div>
<!-- Widget Tag Cloud Ends here -->
</aside>
<!-- Right Side Section End -->
</div>
<section class="cat-box cats-review-box footerSec">
<h2 class="cat-box-title vSec CatArcha">Video
Archives</h2>
<h2 class="cat-box-title CatArchaTitle">Archives</h2>
<div class="cat-box-content">
<div class="reviews-cat">
<div class="CatArchaDiv1">
<div class="CatArchaDiv2">
<ul>
<li>
<a href="https://im4change.in/news-alerts-57/moving-upstream-luni-fellowship.html" target="_blank">
Moving Upstream: Luni – Fellowship </a>
</li>
<li>
<a href="https://im4change.in/news-alerts-57/135-million-indians-exited-multidimensional-poverty-as-per-government-figures-is-that-the-same-as-poverty-reduction.html" target="_blank">
135 Million Indians Exited “Multidimensional" Poverty as per Government... </a>
</li>
<li>
<a href="https://im4change.in/news-alerts-57/explainer-why-are-tomato-prices-on-fire.html" target="_blank">
Explainer: Why are Tomato Prices on Fire? </a>
</li>
<li>
<a href="https://im4change.in/news-alerts-57/nsso-survey-only-39-1-of-all-households-have-drinking-water-within-dwelling-46-7-of-rural-households-use-firewood-for-cooking.html" target="_blank">
NSSO Survey: Only 39.1% of all Households have Drinking... </a>
</li>
<li class="CatArchalLi1">
<a href="https://im4change.in/news-alerts-57"
class="more-link CatArchalAnch1" target="_blank">
More...
</a>
</li>
</ul>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/I51LYnP8BOk/1.jpg"
alt=" Im4Change.org हिंदी वेबसाइट का परिचय. Short Video on im4change.org...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Short-Video-on-im4change-Hindi-website-Inclusive-Media-for-Change" target="_blank">
Im4Change.org हिंदी वेबसाइट का परिचय. Short Video on im4change.org... </a>
</p>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/kNqha-SwfIY/1.jpg"
alt=" "Session 1: Scope of IDEA and AgriStack" in Exploring...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Session-1- Scope-of-IDEA-and-AgriStack-in-Exploring-Digitalisation-in-Agriculture-29-April-2022" target="_blank">
"Session 1: Scope of IDEA and AgriStack" in Exploring... </a>
</p>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/6kIVjlgZItk/1.jpg"
alt=" "Session 2: Farmer Centric Digitalisation in Agriculture" in Exploring...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Session-2-Farmer-Centric-Digitalisation-in-Agriculture-in-Exploring-Digitalisation-in-Agriculture-29-April-2022" target="_blank">
"Session 2: Farmer Centric Digitalisation in Agriculture" in Exploring... </a>
</p>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/2BeHTu0y7xc/1.jpg"
alt=" "Session 3: Future of Digitalisation in Agriculture" in Exploring...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Session-3-Future-of-Digitalisation-in-Agriculture-in-Exploring-Digitalisation-in-Agriculture-29-April-2022" target="_blank">
"Session 3: Future of Digitalisation in Agriculture" in Exploring... </a>
</p>
</div>
<div class="divWidth">
<ul class="divWidthMarg">
<li>
<a href="https://im4change.in/video/Public-Spending-on-Agriculture-in-India-Source-Foundation-for-Agrarian-Studies"
title="Public Spending on Agriculture in India (Source: Foundation for Agrarian Studies)" target="_blank">
Public Spending on Agriculture in India (Source: Foundation for...</a>
</li>
<li>
<a href="https://im4change.in/video/Agrarian-Change-Seminar-Protests-against-the-New-Farm-Laws-in-India-by-Prof-Vikas-Rawal-JNU-Source-Journal-Of-Agrarian-Change"
title="Agrarian Change Seminar: 'Protests against the New Farm Laws in India' by Prof. Vikas Rawal, JNU (Source: Journal Of Agrarian Change) " target="_blank">
Agrarian Change Seminar: 'Protests against the New Farm Laws...</a>
</li>
<li>
<a href="https://im4change.in/video/Webinar-Ramrao-The-Story-of-India-Farm-Crisis-Source-Azim-Premji-University"
title="Webinar: Ramrao - The Story of India's Farm Crisis (Source: Azim Premji University)" target="_blank">
Webinar: Ramrao - The Story of India's Farm Crisis...</a>
</li>
<li>
<a href="https://im4change.in/video/water-and-agricultural-transformation-in-India"
title="Water and Agricultural Transformation in India: A Symbiotic Relationship (Source: IGIDR)" target="_blank">
Water and Agricultural Transformation in India: A Symbiotic Relationship...</a>
</li>
<li class="CatArchalLi1">
<a href="https://im4change.in/videogallery"
class="more-link CatArchalAnch1" target="_blank">
More...
</a>
</li>
</ul>
</div>
</div>
</div>
</div>
</section> </div>
<div class="clear"></div>
<!-- Footer option Starts here -->
<div class="footer-bottom fade-in animated4">
<div class="container">
<div class="social-icons icon_flat">
<p class="SocialMargTop"> Website Developed by <a target="_blank" title="Web Development"
class="wot right"
href="http://www.ravinderkhurana.com/" rel="nofollow">
RAVINDErkHURANA.com</a></p>
</div>
<div class="alignleft">
<a
target="_blank" href="https://im4change.in/objectives-8.html"
class="link"
title="Objectives">Objectives</a> | <a
target="_blank" href="https://im4change.in/about-us-9.html"
class="link" title="About Us">About Us</a> | <a
target="_blank" href="https://im4change.in/media-workshops.php"
class="ucwords">Workshops</a> | <a
target="_blank" href="https://im4change.in/disclaimer/disclaimer-149.html"
title="Disclaimer">Disclaimer</a> </div>
</div>
</div>
<!-- Footer option ends here -->
</div>
<div id="connect">
<a target="_blank"
href="http://www.facebook.com/sharer.php?u=https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575.html"
title="Share on Facebook">
<img src="https://im4change.in/images/Facebook.png?1582080640" alt="share on Facebook" class="ImgBorder"/>
</a><br/>
<a target="_blank"
href="http://twitter.com/share?text=Im4change&url=https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575.html"
title="Share on Twitter">
<img src="https://im4change.in/images/twitter.png?1582080632" alt="Twitter" class="ImgBorder"/> </a>
<br/>
<a href="/feeds" title="RSS Feed" target="_blank">
<img src="https://im4change.in/images/rss.png?1582080632" alt="RSS" class="ImgBorder"/>
</a>
<br/>
<a class="feedback-link" id="feedbackFormLink" href="#">
<img src="https://im4change.in/images/feedback.png?1582080630" alt="Feedback" class="ImgBorder"/>
</a> <br/>
<a href="javascript:function iprl5(){var d=document,z=d.createElement('scr'+'ipt'),b=d.body,l=d.location;try{if(!b)throw(0);d.title='(Saving...) '+d.title;z.setAttribute('src',l.protocol+'//www.instapaper.com/j/WKrH3R7ORD5p?u='+encodeURIComponent(l.href)+'&t='+(new Date().getTime()));b.appendChild(z);}catch(e){alert('Please wait until the page has loaded.');}}iprl5();void(0)"
class="bookmarklet" onclick="return explain_bookmarklet();">
<img src="https://im4change.in/images/read-it-later.png?1582080632" alt="Read Later" class="ImgBorder"/> </a>
</div>
<!-- Feedback form Starts here -->
<div id="feedbackForm" class="overlay_form" class="ImgBorder">
<h2>Contact Form</h2>
<div id="contactform1">
<div id="formleft">
<form id="submitform" action="/contactus.php" method="post">
<input type="hidden" name="submitform" value="submitform"/>
<input type="hidden" name="salt_key" value="a0e0f2c6a0644a70e57ad2c96829709a"/>
<input type="hidden" name="ref" value="feedback"/>
<fieldset>
<label>Name :</label>
<input type="text" name="name" class="tbox" required/>
</fieldset>
<fieldset>
<label>Email :</label>
<input type="text" name="email" class="tbox" required/>
</fieldset>
<fieldset>
<label>Message :</label>
<textarea rows="5" cols="20" name="message" required></textarea>
</fieldset>
<fieldset>
Please enter security code
<div class="clear"></div>
<input type="text" name="vrcode" class="tbox"/>
</fieldset>
<fieldset>
<input type="submit" class="button" value="Submit"/>
<a href="#" id="closefeedbakcformLink">Close</a>
</fieldset>
</form>
</div>
<div class="clearfix"></div>
</div>
</div>
<div id="donate_popup" class="modal" style="max-width: 800px;">
<table width="100%" border="1">
<tr>
<td colspan="2" align="center">
<b>Support im4change</b>
</td>
</tr>
<tr>
<td width="25%" valign="middle">
<img src="https://im4change.in/images/logo2.jpg?1582080632" alt="" width="100%"/> </td>
<td style="padding-left:10px;padding-top:10px;">
<form action="https://im4change.in/donate" method="get">
<table width="100%" cellpadding="2" cellspacing="2">
<tr>
<td width="33%" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
10
</td>
<td width="33%" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
100
</td>
<td width="33%" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
1000
</td>
</tr>
<tr>
<td colspan="3">
</td>
</tr>
<tr>
<td style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
50
</td>
<td style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
500
</td>
<td style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
<input type="text" name="price" placeholder="?" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
</td>
</tr>
<tr>
<td colspan="3">
</td>
</tr>
<tr>
<td colspan="3" align="right">
<input type="button" name="Pay" value="Pay"
style="width: 200px;background-color: rgb(205, 35, 36);color: #ffffff;"/>
</td>
</tr>
</table>
</form>
</td>
</tr>
</table>
</div><script type='text/javascript'>
/* <![CDATA[ */
var tievar = {'go_to': 'Go to...'};
/* ]]> */
</script>
<script src="/js/tie-scripts.js?1575549704"></script><script src="/js/bootstrap.js?1575549704"></script><script src="/js/jquery.modal.min.js?1578284310"></script><script>
$(document).ready(function() {
// tell the autocomplete function to get its data from our php script
$('#s').autocomplete({
source: "/autocomplete"
});
});
</script>
<script src="/vj-main-sw-register.js" async></script>
<script>function init(){var imgDefer=document.getElementsByTagName('img');for(var i=0;i<imgDefer.length;i++){if(imgDefer[i].getAttribute('data-src')){imgDefer[i].setAttribute('src',imgDefer[i].getAttribute('data-src'))}}}
window.onload=init;</script>
</body>
</html>'
}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
$response = object(Cake\Http\Response) {
'status' => (int) 200,
'contentType' => 'text/html',
'headers' => [
'Content-Type' => [
[maximum depth reached]
]
],
'file' => null,
'fileRange' => [],
'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
'cacheDirectives' => [],
'body' => '<!DOCTYPE html>
<!--[if lt IE 7 ]>
<html class="ie ie6" lang='en'> <![endif]-->
<!--[if IE 7 ]>
<html class="ie ie7" lang='en'> <![endif]-->
<!--[if IE 8 ]>
<html class="ie ie8" lang='en'> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!-->
<html lang='en'>
<!--<![endif]-->
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<title>
LATEST NEWS UPDATES | Western warnings-R Ramachandran </title>
<meta name="description" content="
India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines.
AS was only to be expected, the two landmark decisions made by the Indian patent office in recent..."/>
<meta name="keywords" content="Health,patents,medicines"/>
<meta name="news_keywords" content="Health,patents,medicines">
<link rel="alternate" type="application/rss+xml" title="ROR" href="/ror.xml"/>
<link rel="alternate" type="application/rss+xml" title="RSS 2.0" href="/feeds/"/>
<link rel="stylesheet" href="/css/bootstrap.min.css?1697864993"/> <link rel="stylesheet" href="/css/style.css?v=1.1.2"/> <link rel="stylesheet" href="/css/style-inner.css?1577045210"/> <link rel="stylesheet" id="Oswald-css"
href="https://fonts.googleapis.com/css?family=Oswald%3Aregular%2C700&ver=3.8.1" type="text/css"
media="all">
<link rel="stylesheet" href="/css/jquery.modal.min.css?1578285302"/> <script src="/js/jquery-1.10.2.js?1575549704"></script> <script src="/js/jquery-migrate.min.js?1575549704"></script> <link rel="shortcut icon" href="/favicon.ico" title="Favicon">
<link rel="stylesheet" href="/css/jquery-ui.css?1580720609"/> <script src="/js/jquery-ui.js?1575549704"></script> <link rel="preload" as="style" href="https://www.im4change.org/css/custom.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel="preload" as="style" href="https://www.im4change.org/css/jquery.modal.min.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel="preload" as="style" href="https://www.im4change.org/css/jquery-ui.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel="preload" as="style" href="https://www.im4change.org/css/li-scroller.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<!-- <link rel="preload" as="style" href="https://www.im4change.org/css/style.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous"> -->
<link rel="preload" as="style" href="https://www.im4change.org/css/style-inner.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel='dns-prefetch' href="//im4change.org/css/custom.css" crossorigin >
<link rel="preload" as="script" href="https://www.im4change.org/js/bootstrap.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery.li-scroller.1.0.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery.modal.min.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery.ui.totop.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery-1.10.2.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery-migrate.min.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery-ui.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/setting.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/tie-scripts.js">
<!--[if IE]>
<script type="text/javascript">jQuery(document).ready(function () {
jQuery(".menu-item").has("ul").children("a").attr("aria-haspopup", "true");
});</script>
<![endif]-->
<!--[if lt IE 9]>
<script src="/js/html5.js"></script>
<script src="/js/selectivizr-min.js"></script>
<![endif]-->
<!--[if IE 8]>
<link rel="stylesheet" type="text/css" media="all" href="/css/ie8.css"/>
<![endif]-->
<meta property="og:title" content="LATEST NEWS UPDATES | Western warnings-R Ramachandran" />
<meta property="og:url" content="https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575.html" />
<meta property="og:type" content="article" />
<meta property="og:description" content="
India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines.
AS was only to be expected, the two landmark decisions made by the Indian patent office in recent..." />
<meta property="og:image" content="" />
<meta property="fb:app_id" content="0" />
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no">
<link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://im4change.in/images/apple1.png">
<link rel="apple-touch-icon-precomposed" sizes="120x120" href="https://im4change.in/images/apple2.png">
<link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://im4change.in/images/apple3.png">
<link rel="apple-touch-icon-precomposed" href="https://im4change.in/images/apple4.png">
<style>
.gsc-results-wrapper-overlay{
top: 38% !important;
height: 50% !important;
}
.gsc-search-button-v2{
border-color: #035588 !important;
background-color: #035588 !important;
}
.gsib_a{
height: 30px !important;
padding: 2px 8px 1px 6px !important;
}
.gsc-search-button-v2{
height: 41px !important;
}
input.gsc-input{
background: none !important;
}
@media only screen and (max-width: 600px) {
.gsc-results-wrapper-overlay{
top: 11% !important;
width: 87% !important;
left: 9% !important;
height: 43% !important;
}
.gsc-search-button-v2{
padding: 10px 10px !important;
}
.gsc-input-box{
height: 28px !important;
}
/* .gsib_a {
padding: 0px 9px 4px 9px !important;
}*/
}
@media only screen and (min-width: 1200px) and (max-width: 1920px) {
table.gsc-search-box{
width: 15% !important;
float: right !important;
margin-top: -118px !important;
}
.gsc-search-button-v2 {
padding: 6px !important;
}
}
</style>
<script>
$(function () {
$("#accordion").accordion({
event: "click hoverintent"
});
});
/*
* hoverIntent | Copyright 2011 Brian Cherne
* http://cherne.net/brian/resources/jquery.hoverIntent.html
* modified by the jQuery UI team
*/
$.event.special.hoverintent = {
setup: function () {
$(this).bind("mouseover", jQuery.event.special.hoverintent.handler);
},
teardown: function () {
$(this).unbind("mouseover", jQuery.event.special.hoverintent.handler);
},
handler: function (event) {
var currentX, currentY, timeout,
args = arguments,
target = $(event.target),
previousX = event.pageX,
previousY = event.pageY;
function track(event) {
currentX = event.pageX;
currentY = event.pageY;
}
;
function clear() {
target
.unbind("mousemove", track)
.unbind("mouseout", clear);
clearTimeout(timeout);
}
function handler() {
var prop,
orig = event;
if ((Math.abs(previousX - currentX) +
Math.abs(previousY - currentY)) < 7) {
clear();
event = $.Event("hoverintent");
for (prop in orig) {
if (!(prop in event)) {
event[prop] = orig[prop];
}
}
// Prevent accessing the original event since the new event
// is fired asynchronously and the old event is no longer
// usable (#6028)
delete event.originalEvent;
target.trigger(event);
} else {
previousX = currentX;
previousY = currentY;
timeout = setTimeout(handler, 100);
}
}
timeout = setTimeout(handler, 100);
target.bind({
mousemove: track,
mouseout: clear
});
}
};
</script>
<script type="text/javascript">
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-472075-3']);
_gaq.push(['_trackPageview']);
(function () {
var ga = document.createElement('script');
ga.type = 'text/javascript';
ga.async = true;
ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
var s = document.getElementsByTagName('script')[0];
s.parentNode.insertBefore(ga, s);
})();
</script>
<link rel="stylesheet" href="/css/custom.css?v=1.16"/> <script src="/js/jquery.ui.totop.js?1575549704"></script> <script src="/js/setting.js?1575549704"></script> <link rel="manifest" href="/manifest.json">
<meta name="theme-color" content="#616163" />
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-status-bar-style" content="black">
<meta name="apple-mobile-web-app-title" content="im4change">
<link rel="apple-touch-icon" href="/icons/logo-192x192.png">
</head>
<body id="top" class="home inner blog">
<div class="background-cover"></div>
<div class="wrapper animated">
<header id="theme-header" class="header_inner" style="position: relative;">
<div class="logo inner_logo" style="left:20px !important">
<a title="Home" href="https://im4change.in/">
<img src="https://im4change.in/images/logo2.jpg?1582080632" class="logo_image" alt="im4change"/> </a>
</div>
<div class="langhindi" style="color: #000;display:none;"
href="https://im4change.in/">
<a class="more-link" href="https://im4change.in/">Home</a>
<a href="https://im4change.in/hindi/" class="langbutton ">हिन्दी</a>
</div>
<nav class="fade-in animated2" id="main-nav">
<div class="container">
<div class="main-menu">
<ul class="menu" id="menu-main">
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children"
style="left: -40px;"><a
target="_blank" href="https://im4change.in/">Home</a>
</li>
<li class="menu-item mega-menu menu-item-type-taxonomy mega-menu menu-item-object-category mega-menu menu-item-has-children parent-list"
style=" margin-left: -40px;"><a href="#">KNOWLEDGE GATEWAY <span class="sub-indicator"></span>
</a>
<div class="mega-menu-block background_menu" style="padding-top:25px;">
<div class="container">
<div class="mega-menu-content">
<div class="mega-menu-item">
<h3><b>Farm Crisis</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/farmers039-suicides-14.html"
class="left postionrel">Farm Suicides </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/unemployment-30.html"
class="left postionrel">Unemployment </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/rural-distress-70.html"
class="left postionrel">Rural distress </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/migration-34.html"
class="left postionrel">Migration </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/key-facts-72.html"
class="left postionrel">Key Facts </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/debt-trap-15.html"
class="left postionrel">Debt Trap </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Empowerment</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/union-budget-73.html"
class="left postionrel">Union Budget And Other Economic Policies </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/forest-and-tribal-rights-61.html"
class="left postionrel">Forest and Tribal Rights </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-education-60.html"
class="left postionrel">Right to Education </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-food-59.html"
class="left postionrel">Right to Food </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/displacement-3279.html"
class="left postionrel">Displacement </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-work-mg-nrega-39.html"
class="left postionrel">Right to Work (MG-NREGA) </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/gender-3280.html"
class="left postionrel">GENDER </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-information-58.html"
class="left postionrel">Right to Information </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/social-audit-48.html"
class="left postionrel">Social Audit </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Hunger / HDI</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/poverty-and-inequality-20499.html"
class="left postionrel">Poverty and inequality </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/malnutrition-41.html"
class="left postionrel">Malnutrition </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/public-health-51.html"
class="left postionrel">Public Health </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/education-50.html"
class="left postionrel">Education </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/hunger-overview-40.html"
class="left postionrel">Hunger Overview </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/hdi-overview-45.html"
class="left postionrel">HDI Overview </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/pds-ration-food-security-42.html"
class="left postionrel">PDS/ Ration/ Food Security </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/sdgs-113.html"
class="left postionrel">SDGs </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/mid-day-meal-scheme-mdms-53.html"
class="left postionrel">Mid Day Meal Scheme (MDMS) </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Environment</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/environment/time-bomb-ticking-52.html"
class="left postionrel">Time Bomb Ticking </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/environment/water-and-sanitation-55.html"
class="left postionrel">Water and Sanitation </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/environment/impact-on-agriculture-54.html"
class="left postionrel">Impact on Agriculture </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Law & Justice</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/social-justice-20500.html"
class="left postionrel">Social Justice </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/access-to-justice-47.html"
class="left postionrel">Access to Justice </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/human-rights-56.html"
class="left postionrel">Human Rights </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/corruption-35.html"
class="left postionrel">Corruption </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/general-insecurity-46.html"
class="left postionrel">General Insecurity </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/disaster-relief-49.html"
class="left postionrel">Disaster & Relief </a>
</p>
</div>
</div>
</div>
</div>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page "><a target="_blank" href="https://im4change.in/nceus_reports.php">NCEUS reports</a>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children parent-list ">
<a target="_blank" href="https://im4change.in/about-us-9.html">About Us <span
class="sub-indicator"></span></a>
<ul class="sub-menu aboutmenu">
<li class="menu-item menu-item-type-post_type menu-item-object-page"><a
target="_blank" href="https://im4change.in/objectives-8.html">Objectives</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page"><a
target="_blank" href="https://im4change.in/contactus.php">Contact
Us</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page"><a
target="_blank" href="https://im4change.in/about-us-9.html">About
Us</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children ">
<a target="_blank" href="https://im4change.in/fellowships.php" title="Fellowships">Fellowships</a>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children "><a
target="_blank" href="https://im4change.in/media-workshops.php">Workshops</a>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children "><a
target="_blank" href="https://im4change.in/research.php">Research</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children "><a
target="_blank" href="https://im4change.in/links-64">Partners</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children"
id="menu-item-539"><a target="_blank" href="https://im4change.in/hindi/"
class="langbutton langlinkfont17">हिन्दी</a></li>
</ul>
</div> </div>
<!-- <div style="float: right;">
<script async src="https://cse.google.com/cse.js?cx=18b4f2e0f11bed3dd"></script>
<div class="gcse-search"></div>
</div> -->
<div class="search-block" style=" margin-left: 8px; margin-right: 7px;">
<form method="get" id="searchform" name="searchform"
action="https://im4change.in/search"
onsubmit="return searchvalidate();">
<button class="search-button" type="submit" value="Search"></button>
<input type="text" id="s" name="qryStr" value=""
onfocus="if (this.value == 'Search...') {this.value = '';}"
onblur="if (this.value == '') {this.value = 'Search...';}">
</form>
</div>
</nav>
</header>
<div class="container">
<div id="main-content" class=" main1 container fade-in animated3 sidebar-narrow-left">
<div class="content-wrap">
<div class="content" style="width: 900px;min-height: 500px;">
<section class="cat-box recent-box innerCatRecent">
<h1 class="cat-box-title">Western warnings-R Ramachandran</h1>
<a href="JavaScript:void(0);" onclick="return shareArticle(14451);">
<img src="https://im4change.in/images/email.png?1582080630" border="0" width="24" align="right" alt="Share this article"/> </a>
<a href="https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575/print"
rel="nofollow">
<img src="https://im4change.in/images/icon-print.png?1582080630" border="0" width="24" align="right" alt="Share this article"/>
</a>
</section>
<section class="recent-box innerCatRecent">
<small class="pb-1"><span class="dateIcn">
<img src="https://im4change.in/images/published.svg?1582080666" alt="published"/>
Published on</span><span class="text-date"> Apr 20, 2012</span>
<span
class="dateIcn">
<img src="https://im4change.in/images/modified.svg?1582080666" alt="modified"/> Modified on </span><span class="text-date"> Apr 20, 2012</span>
</small>
</section>
<div class="clear"></div>
<div style="padding-top: 10px;">
<div class="innerLineHeight">
<div class="middleContent innerInput latest-news-updates">
<table>
<tr>
<td>
<div>
<br /><div align="justify"><em>India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines. <br /></em><br />AS was only to be expected, the two landmark decisions made by the Indian patent office in recent times concerning pharmaceutical patent cases have not gone down well with the multinational drug industry. First, there was the rejection in 2006 of the patent application by the Swiss multinational Novartis for imatinib mesylate (sold under the brand name of Glivec, or Gleevec), its incrementally modified drug for leukaemia, or blood cancer. Then, on March 12, 2012, the Indian generic drug company Natco Pharma Ltd was granted a manufacturing licence to produce a generic version of the patented liver and kidney cancer drug sorafenib tosylate of the German multinational company (MNC) Bayer (brand name Nexavar) through the first-ever invocation of the compulsory licence (CL) provision in the Indian Patents Act, 1970 (as amended in 2005). The CL was granted to ensure affordability of the drug to Indian cancer patients. Natco will now produce the drug at a price that will be 97 per cent lower than Bayer's even after paying 6 per cent royalty on net sales to Bayer.<br /><br />Bayer will most likely appeal against the order. Novartis challenged the patent office's rejection of its patent application first at the Intellectual Property Appellate Board (IPAB) and subsequently in the Madras High Court. Both upheld the Patent Controller's decision and rejected Novartis' appeals against the Indian government. Now the company has appealed to the Supreme Court. The first hearing is slated for July 10. These two cases have demonstrated how flexibilities available in the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement (for patent protection) of the World Trade Organisation (WTO) can be successfully used to serve public health interests in developing countries over the interests of the private monopoly of profit-driven drug MNCs. The flexibilities in the TRIPS Agreement allow governments to decide what type of “innovation” is patentable. The criteria of “novelty”, “inventive step”, and “industrial applicability” are not defined in the agreement and are left for individual governments to determine within existing national legislation and circumstances. These are also, therefore, test cases for the Indian judiciary, and if these orders can be sustained in the face of imminent legal battles, they will serve as important precedents for exploiting the full power of the Indian Patents Act, while conforming to the WTO's intellectual property rights (IPR) regime, to ensure the Indian public access to health care it can afford.<br /><br />Drug majors around the world, American companies in particular, which have, of course, been watching the Novartis case anxiously for the past five years, have been further jolted by the latest decision on Nexavar. The president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), John Castellani, issued the following statement immediately after India granted the CL for the indigenous production of Nexavar's generic version:<br /><br />“While India has not routinely issued CLs, PhRMA believes it is not an appropriate tool even if granting CLs may be a legal option.… Legitimate health emergencies that require making exceptions to IPRs can, and should, be accommodated under the international framework, but only after exhausting all other efforts and under extraordinary circumstances…. [O]ne aspect that is particularly troublesome is the contention that ‘working' a patent requires a company to manufacture within India. It is our firm belief that this is fully at odds with India's TRIPS commitments (as well as broader WTO obligations), and distorts what was intended as a public health exception into an industrial policy…. CLs cannot solve India's larger problems regarding access to medicines and health care.”<br /><br />The PhRMA's contentions are patently wrong as the decision is in full compliance with the Doha “Declaration on the TRIPS Agreement and Public Health” of November 2001 and Article 31 of TRIPS. But the protest was conveyed more brazenly to the Indian government when the visiting United States Commerce Secretary, John Bryson, raised the issue of India granting a CL to Natco in his meeting with Commerce and Industry Minister Anand Sharma on March 25. Bryson apparently said that any dilution of the international patent regime was a cause for deep concern for the U.S. This was clearly an unwarranted remark on the part of the U.S. official because if there was any perceived violation of TRIPS, the correct forum for the U.S. to address the issue was the WTO.<br /><br />The U.S. has instituted an internal mechanism under its trade policy to deal with what it perceives as trade barriers in its trading-partner countries on the basis of an annual assessment in what is called the “Special 301 Report” by the office of the U.S. Trade Representative (USTR). India has consistently been placed in the “Priority Watch List” of the report. Following the court's rejection of Novartis' appeal in 2009, the 2010 report included a response of the USTR to the Indian decision.<br /><br />The report said: “The United States continues to urge India to improve its IPR regime by providing stronger protection for patents. One concern in this regard is a provision in India's Patent Law that prohibits patents on certain chemical forms absent a showing of increased efficacy. While the full import of this provision remains unclear, it appears to limit the patentability of potentially beneficial innovations, such as temperature-stable forms of a drug or new means of drug delivery” (emphasis added, throughout).<br /><br />The wording clearly reflects the U.S.' objection to the Indian patent office not granting a new patent for a new chemical form of a patented drug that the manufacturer claims had increased bioabsorption but for which there was no proven increased therapeutic efficacy. The 2011 report, too, essentially repeated the same objection to the restricted scope of patentability of drugs under the Patents Act. The administration's objection to the Bayer-Nexavar case is bound to be reflected in the 2012 report, given that the PhRMA has already voiced its protest. Drugs are big business around the world for the U.S. industry, and the PhRMA, which acts as the prime lobby group for the U.S. drug industry, naturally has a major influence on the contents of the Special 301 Report.<br /><br />In its submission to the USTR on the 2012 Special 301 Report, the PhRMA said the following with regard to the patentability criteria exercised by the Indian patent office in the Novartis case: “Some of the standards for patentability in India are not transparent and are inconsistent with the TRIPS Agreement. For example, Section 3(d) of the [Indian] Patents Act… creates additional hurdles to the grant of certain chemical compound patents, and appears to be applied only to pharmaceuticals. Under this provision, salts, esters, ethers, polymorphs, and other derivatives of known substances are presumed to be the same substance as the original chemical and thus not patentable, unless it can be shown that they differ significantly in properties with regard to efficacy. These additional requirements for patentability beyond novelty, commercial applicability and non-obviousness are inconsistent with the TRIPS Agreement.... Article 27 of the TRIPS Agreement provides a non-extendable list of the types of subject matter that can be excluded from patent coverage. This list does not include ‘new forms of known substances lacking enhanced efficacy', as excluded by Section 3(d) of the Indian law.” This argument is misplaced because the rejection is on the grounds of the new drug not meeting the basic criterion of patentability, which is novelty, meaning that it should be a new compound and should involve an inventive step. Novartis was seeking a patent for just the beta crystalline variant of a patented amorphous molecule, claiming merely better bioavailability. Such an incremental modification is not something that involves inventiveness, the court contended.<br /><br />On the issue of CLs, which is another key issue of concern to the PhRMA, its submission, made in February, a month before the decision on the Bayer case was pronounced, stated: “Domestic companies have started filing CL applications with the Indian patent office, apparently prompted in part by government statements suggesting that CLs may be a means for ensuring availability and affordability of drugs worldwide…. At a minimum, India should ensure that the CL provisions comply with TRIPS by... eliminating price as a trigger to CL.” (Section 84(1) (b) of the Indian Patents Act permits a CL if the patented invention is not available to the public at a “reasonably affordable price”.)<br /><br />This again is a misplaced objection because a country is free to decide on the reasons for granting a CL as is clear from the Doha Declaration, which says: “Each member has the right to grant compulsory licences and the freedom to determine the grounds upon which such licences are granted; Each member has the right to determine what constitutes a national emergency or other circumstances of extreme urgency, it being understood that public health crises, including those relating to HIV/AIDS, tuberculosis, malaria and other epidemics, can represent a national emergency or other circumstances of extreme urgency.” The patent office exercised the freedom of granting the CL to Natco on the issue of affordability, given that Natco's generic drug will cost Rs.8,800 a month as against Bayer's Rs.2.8 lakh a month and that cancer treatment is lifelong.<br /><br />Retaliation following the listing of a country on the watch list includes the U.S. initiating dispute settlement mechanisms at international trade forums such as the WTO, elimination of preferential tariff preferences under bilateral trade agreements, if any, and even unilateral trade sanctions against the named country. Bryson's remarks are perhaps a veiled threat of such action against India since there are many such pharmaceutical patent cases pending in Indian courts for which these cases could become precedents, affecting the potentially huge market of American MNCs.<br />Trade policy forum<br /><br />There exists a bilateral engagement between India and the U.S. under what is called the U.S.-India Trade Policy Forum (TPF) formed in 2005 alongside the various India-U.S. agreements that came into being, including the nuclear deal. The TPF has five focus groups: agriculture, investment, innovation and creativity (IPR), services, and tariff and non-tariff barriers. Under the TPF, a framework for cooperation and trade was signed two years ago.<br /><br />Although its proposed work plan does not specifically mention IPR, it does include a group focussing on tariff and non-tariff barriers, which is aimed at “promoting policies to expand market access, including adopting transparent, WTO-policies….” It is quite likely that this bilateral forum will begin to be used by the U.S. to bring on pressure on contentious issues concerning IPR.<br /><br />Interestingly, the scheduled meeting of the TPF has been postponed twice by the U.S. since October, the most recent being the meeting of the Commerce Minister with USTR Ron Kirk in January. According to media reports, this is because of insufficient progress achieved on the various issues, increasing market access to U.S. companies, in particular. Clearly, the U.S. will increase pressure on the IPR issue in the wake of the recent CL decision at the next meeting of the TPF, which has been pushed to mid-2012. The Indian government would do well to guard against that. Health-care activists and IPR experts have voiced similar concern over the proposed India-European Union (E.U.) Free Trade Agreement (FTA).<br /><br />According to reports, the 27-nation bloc has been pressing India to agree to an IPR regime over and above TRIPS. This demand is related to the area of pharmaceuticals, particularly after the Novartis decision, and this demand in all likelihood will become stronger now. Recently, however, Minister Anand Sharma assured a visiting UNAIDS (Joint United Nations Programme on HIV/AIDS) executive that India would reject efforts to include a “data exclusivity” clause in bilateral agreements and affirmed the Indian government's full commitment to ensure quality generic medicines through compulsory licensing and other TRIPS flexibilities. Notwithstanding this, in a recent article in The Guardian, Philippe Douste-Blazy, U.N. Special Adviser on Innovative Financing for Development, and Denis Broun, Executive Director of Unitaid, an international facility for the purchase of drugs for HIV/AIDS, malaria and tuberculosis hosted by the World Health Organisation in Geneva, wrote: “If stringent patent and border measures are agreed on at the E.U.-India FTA summit, patients in poor countries will no longer have access to cheap generic medicines; India's role as the ‘pharmacy of the South' could well come to an end.”<br /><br />The U.S. has already begun to exert such pressures and force countries in some other parts of the world into accepting IPR protection standards that are stronger than the TRIPS regime. Under the Trans-Pacific Partnership, a multilateral free trade agreement between the U.S. and the countries of the Asia-Pacific region that seeks to further liberalise these economies, the U.S. intends to broaden the scope of patentability by eroding the flexibility afforded by TRIPS by requesting TPP partner countries to pass new laws and rules that severely limit the ability of each country to define what is “patentable”. The nine countries currently negotiating the TPP are Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the U.S. and Vietnam. Japan and South Korea are intending to join the group shortly.<br /><br />A leaked draft of the chapter on IPR in a U.S.-negotiating TPP text, which reflects the U.S. position on this multilateral arrangement, indicates that the U.S. is demanding aggressive IPR provisions that go beyond what international trade law (under TRIPS) requires: “Each Party,” says the draft U.S. proposal, “ shall confirm that: patents shall be available for any new forms, uses, or methods of using a known product; and a new form, use, or method of using a known product may satisfy the criteria for patentability, even if such invention does not result in the enhancement of the known efficacy of that product.” This is the “patent evergreening” technique that Novartis tried to employ, which the Indian patent office rejected. Evergreening of a patent allows pharmaceutical companies to obtain or extend monopoly protection for old drugs simply by making minor modifications to existing formulae. The international organisation Medecins Sans Frontieres (Doctors Without Borders), which provides affordable health care around the world, points out: “Evergreening significantly delays the arrival of more affordable generic medicines into the market.” The TPP draft text further wants plants and animals and diagnostic, therapeutic and surgical methods for the treatment of humans or animals, which are explicitly ruled by TRIPS to be non-patentable, to be patentable.<br /><br />In addition, another leaked document pertaining to the TPP seeks to eliminate the process of pre-grant opposition to a patent application, which is an important tool to prevent patent applications based on weak or erroneous information. The U.S. proposal, if accepted, would allow opposition only after the patent is granted.<br /><br />Although this does not directly or immediately affect the Indian situation, it does portend ominous moves on this front by the U.S. on India as well. This is evident from the remarks Ron Kirk made recently: “U.S. involvement in the TPP is predicated on the expansion of the agreement to include more economies in the Asia-Pacific region…[and] should set the standard for 21st century trade agreements going forward.”<br /><br />It, therefore, stands to reason that the norms that emerge from the TPP negotiations will serve as the template for future U.S. trade agreements across the world. Using the leverage of the many countries in the TPP fold, and perhaps in other bilateral agreements, which accept this new enlarged premise for patentability, the WTO, too, eventually might come under pressure to change its rules of dispute settlement and arbitration. The implications of this are that IPR regimes, in particular the strict patentability criteria for drugs, of countries such as India, which have the responsibility of extending affordable health care to millions, will increasingly come under severe attack from the U.S. and the E.U., where nearly all the big drug multinationals operate and profit at the cost of the suffering poor of developing countries.</div>
</div>
</td>
</tr>
</table>
</div>
</div>
</div>
<div class="clear"></div>
<br><a href="http://www.frontlineonnet.com/stories/20120504290801800.htm" class="re" target="_blank">Frontline, Volume 29, Issue 08, 21 April-04 May, 2012, http://www.frontlineonnet.com/stories/20120504290801800.htm</a><div class="clear"></div>
<div style="padding-top: 18px;">
<p class="post-tag">Tagged with:
<a class="tagcloud5"
href="https://im4change.in/search?qryStr=Health"
title="Health">
Health </a>
<a class="tagcloud5"
href="https://im4change.in/search?qryStr=patents"
title="patents">
patents </a>
<a class="tagcloud5"
href="https://im4change.in/search?qryStr=medicines"
title="medicines">
medicines </a>
</p>
</div>
<div class="clear"></div>
<br><br>
<div class="widget-top">
<h4>Related Articles</h4>
<div class="stripe-line"></div>
</div>
<div class="widget-container">
<ul id="recentcomments">
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/fifth-report-from-gambia-implicates-indian-drug-maker-for-contaminated-syrups-banjot-kaur.html"
title="Fifth Report From Gambia Implicates Indian Drug Maker for Contaminated Syrups - Banjot Kaur">
Fifth Report From Gambia Implicates Indian Drug Maker for Contaminated Syrups - Banjot Kaur </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/india-may-have-seen-steepest-dip-in-multidimensional-poverty-among-110-nations-as-per-undp-data-nikhil-rampal.html"
title="India may have seen steepest dip in multidimensional poverty among 110 nations as per UNDP data - Nikhil Rampal">
India may have seen steepest dip in multidimensional poverty among 110 nations as per UNDP data - Nikhil Rampal </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/health-among-top-three-priorities-for-indian-voters-after-jobs-and-education-survey-shows-oliver-heath-jyoti-mishra-louise-tillin-sandhya-venkateswaran.html"
title="Health among top three priorities for Indian voters after jobs and education, survey shows - Oliver Heath, Jyoti Mishra, Louise Tillin & Sandhya Venkateswaran">
Health among top three priorities for Indian voters after jobs and education, survey shows - Oliver Heath, Jyoti Mishra, Louise Tillin & Sandhya Venkateswaran </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/prevalence-of-zero-food-among-infants-and-young-children-in-india-patterns-of-change-across-the-states-and-union-territories-of-india-1993-2021-the-lancet.html"
title="Prevalence of Zero-Food among infants and young children in India - The Lancet ">
Prevalence of Zero-Food among infants and young children in India - The Lancet </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/india-s-sustainability-goals-at-risk-because-of-extreme-heatwaves-carbon-copy.html"
title="India's Sustainability Goals at Risk Because of Extreme Heatwaves - Carbon Copy">
India's Sustainability Goals at Risk Because of Extreme Heatwaves - Carbon Copy </a>
</li>
</ul>
</div>
<div class="comment-respond" id="respond">
<a name="commentbox"> </a>
<h3 class="comment-reply-title" id="reply-title">Write Comments</h3>
<form method="post" accept-charset="utf-8" role="form" action="/latest-news-updates/western-warnings-r-ramachandran-14575.html"><div style="display:none;"><input type="hidden" name="_method" value="POST"/></div> <form class="comment-form" id="commentform" method="post" action="#commentbox" onSubmit="return validate()"
name="cmtform">
<input type="hidden" name="cmttype" value="articlecmt"/>
<input type="hidden" name="article_id" value="14451"/>
<p class="comment-notes">Your email address will not be published. Required fields are marked <span
class="required">*</span></p>
<p class="comment-form-author">
<label for="commenterName">Name</label>
<span class="required">*</span>
<input type="text" aria-required="true" size="30"
value=""
name="commenterName" id="commenterName" required="true">
</p>
<p class="comment-form-email">
<label for="commenterEmail">Email</label> <span class="required">*</span>
<input aria-required="true" size="30" name="commenterEmail" id="commenterEmail" type="email"
value=""
required="true">
</p>
<p class="comment-form-contact">
<label for="commenterPh">Contact No.</label>
<input type="text" size="30"
value=""
name="commenterPh" id="commenterPh">
</p>
<p class="comment-form-comment">
<label for="comment">Comment</label>
<textarea aria-required="true" required="true" rows="8" cols="45" name="comment"
id="comment"></textarea>
</p>
<p class="comment-form-comment">
<label for="comment">Type the characters you see in the image below <span class="required">*</span><br><img
class="captchaImg"
src="https://im4change.in/securimage_show_art.php?tk=462617871" alt="captcha"/>
</label>
</p>
<input type="text" name="vrcode" required="true"/>
<p class="form-submit" style="width: 200px;">
<input type="submit" value="Post Comment" id="submit" name="submit">
</p></form>
</div>
<style>
.ui-widget-content {
height: auto !important;
}
</style>
<div id="share-modal"></div>
<style>
.middleContent a{
background-color: rgba(108,172,228,.2);
}
.middleContent a:hover{
background-color: #418fde;
border-color: #418fde;
color: #000;
}
</style>
<script>
function shareArticle(article_id) {
var options = {
modal: true,
height: 'auto',
width: 600 + 'px'
};
$('#share-modal').html("");
$('#share-modal').load('https://im4change.in/share_article?article_id=' + article_id).dialog(options).dialog('open');
}
function postShare() {
var param = 'article_id=' + $("#article_id").val();
param = param + '&y_name=' + $("#y_name").val();
param = param + '&y_email=' + $("#y_email").val();
param = param + '&f_name=' + $("#f_name").val();
param = param + '&f_email=' + $("#f_email").val();
param = param + '&y_msg=' + $("#y_msg").val();
$.ajax({
type: "POST",
url: 'https://im4change.in/post_share_article',
data: param,
success: function (response) {
$('#share-modal').html("Thank You, Your message posted to ");
}
});
return false;
}
</script> </div>
</div>
<!-- Right Side Section Start -->
<!-- MAP Section START -->
<aside class="sidebar indexMarg">
<div class="ad-cell">
<a href="https://im4change.in/statemap.php" title="">
<img src="https://im4change.in/images/map_new_version.png?1582080666" alt="India State Map" class="indiamap" width="232" height="252"/> </a>
<div class="rightmapbox">
<div id="sideOne" class="docltitle"><a href="https://im4change.in/state-report/india/36" target="_blank">DOCUMENTS/
REPORTS</a></div>
<div id="sideTwo" class="statetitle"><a href="https://im4change.in/states.php"target="_blank">STATE DATA/
HDRs.</a></div>
</div>
<div class="widget widgePadTop"></div>
</div>
</aside>
<!-- MAP Section END -->
<aside class="sidebar sidePadbottom">
<div class="rightsmlbox1" >
<a href="https://im4change.in/knowledge_gateway" target="_blank" style="color: #035588;
font-size: 17px;">
KNOWLEDGE GATEWAY
</a>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title">
<a href="https://im4change.in/newsletter" target="_blank">
NEWSLETTER
</a>
</p>
</div>
</div>
<div class="rightsmlbox1" style="height: 325px;">
<div>
<p class="rightsmlbox1_title">
Interview with Prof. Ravi Srivastava
</p>
<p class="rightsmlbox1_title">
<a href="https://im4change.in/video/interview-with-prof-ravi-srivastava-on-current-economic-crisis">
<img width="250" height="200" src="/images/interview_video_home.jpg" alt="Interview with Prof. Ravi Srivastava"/>
</a>
<!--
<iframe width="250" height="200" src="https://www.youtube.com/embed/MmaTlntk-wc" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen=""></iframe>-->
</p>
<a href="https://im4change.in/videogallery" class="more-link CatArchalAnch1" target="_blank">
More videos
</a>
</div>
</div>
<div class="rightsmlbox1">
<div>
<!--div id="sstory" class="rightboxicons"></div--->
<p class="rightsmlbox1_title"><a href="https://im4change.in/list-success-stories" target="_blank">Success Stories</a></p>
</div>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title"><a
href="https://im4change.in/interviews" target="_blank">Interviews</a>
</p>
</div>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title"><a href="https://www.commoncause.in/page.php?id=10" >Donate</a></p>
</div>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title"><a
href="https://im4change.in/marquee"
class="isf_link more-link" title="India Focus?" style="border: 4px solid #fdd922;width: 90%;background-color: #fdd922;text-align: center;color: #000000;font-size:18px" target="_blank">India Focus</a></p> </div>
</div>
<div class="rightsmlbox1" style="height: 104px !important;">
<a href="https://im4change.in/quarterly_reports.php" target="_blank">
Quarterly Reports on Effect of Economic Slowdown on Employment in India (2008 - 2015)
</a>
</div>
<!-- <div class="rightsmlbox1">
<a href="https://play.google.com/store/apps/details?id=com.im4.im4change" target="_blank">
</a></div> -->
<!-- <section class="cat-box recent-box secMarg">
<h2 class="cat-box-title">Most Visited</h2>
</section> -->
<!-- accordion Starts here -->
<!-- <div id="accordion" class="accordMarg">
</div> -->
<!-- accordion ends here -->
<!-- Widget Tag Cloud Starts here -->
<div id="tag_cloud-2" class="widget widget_tag_cloud">
<section class="cat-box recent-box secMarg">
<h2 class="cat-box-title">MOST VISITED TAGS</h2>
</section>
<div class="widget-top wiPdTp">
<div class="stripe-line"></div>
</div>
<div class="widget-container">
<div class="tagcloud">
<a href="https://im4change.in/search?qryStr=Agriculture"
target="_blank" class="tag-link-4 font4">Agriculture</a>
<a href="https://im4change.in/search?qryStr=Food Security"
target="_blank" class="tag-link-4 font4">Food Security</a>
<a href="https://im4change.in/search?qryStr=Law and Justice"
target="_blank" class="tag-link-4 font4">Law and Justice</a>
<a href="https://im4change.in/search?qryStr=Health"
target="_blank" class="tag-link-4 font4">Health</a>
<a href="https://im4change.in/search?qryStr=Right to Food"
target="_blank" class="tag-link-4 font4">Right to Food</a>
<a href="https://im4change.in/search?qryStr=Corruption"
target="_blank" class="tag-link-4 font4">Corruption</a>
<a href="https://im4change.in/search?qryStr=farming"
target="_blank" class="tag-link-4 font4">farming</a>
<a href="https://im4change.in/search?qryStr=Environment"
target="_blank" class="tag-link-4 font4">Environment</a>
<a href="https://im4change.in/search?qryStr=Right to Information"
target="_blank" class="tag-link-4 font4">Right to Information</a>
<a href="https://im4change.in/search?qryStr=NREGS"
target="_blank" class="tag-link-4 font4">NREGS</a>
<a href="https://im4change.in/search?qryStr=Human Rights"
target="_blank" class="tag-link-4 font4">Human Rights</a>
<a href="https://im4change.in/search?qryStr=Governance"
target="_blank" class="tag-link-4 font4">Governance</a>
<a href="https://im4change.in/search?qryStr=PDS"
target="_blank" class="tag-link-4 font4">PDS</a>
<a href="https://im4change.in/search?qryStr=COVID-19"
target="_blank" class="tag-link-4 font4">COVID-19</a>
<a href="https://im4change.in/search?qryStr=Land Acquisition"
target="_blank" class="tag-link-4 font4">Land Acquisition</a>
<a href="https://im4change.in/search?qryStr=mgnrega"
target="_blank" class="tag-link-4 font4">mgnrega</a>
<a href="https://im4change.in/search?qryStr=Farmers"
target="_blank" class="tag-link-4 font4">Farmers</a>
<a href="https://im4change.in/search?qryStr=transparency"
target="_blank" class="tag-link-4 font4">transparency</a>
<a href="https://im4change.in/search?qryStr=Gender"
target="_blank" class="tag-link-4 font4">Gender</a>
<a href="https://im4change.in/search?qryStr=Poverty"
target="_blank" class="tag-link-4 font4">Poverty</a>
<a href="https://im4change.in/search?qryStr=Farm Laws" target="_blank" class="tag-link-4 font4">Farm Laws
</a>
<a href="https://im4change.in/search?qryStr=Citizenship Amendment Act" target="_blank" class="tag-link-4 font4">Citizenship Amendment Act
</a>
<a href="https://im4change.in/search?qryStr=CAA NPR NRIC" target="_blank" class="tag-link-4 font4">CAA NPR NRIC
</a>
<a href="https://im4change.in/search?qryStr=Job Losses" target="_blank" class="tag-link-4 font4">Job Losses
</a>
<a href="https://im4change.in/search?qryStr=Migrant Workers" target="_blank" class="tag-link-4 font4">Migrant Workers
</a>
<a href="https://im4change.in/search?qryStr=Unemployment" target="_blank" class="tag-link-4 font4">Unemployment
</a>
<a href="https://im4change.in/search?qryStr=PMGKAY" target="_blank" class="tag-link-4 font4">PMGKAY
</a>
<a href="https://im4change.in/search?qryStr=PM-KISAN" target="_blank" class="tag-link-4 font4">PM-KISAN
</a>
<a href="https://im4change.in/search?qryStr=PM-CARES" target="_blank" class="tag-link-4 font4">PM-CARES
</a>
<a href="https://im4change.in/search?qryStr=LFPR" target="_blank" class="tag-link-4 font4">LFPR
</a>
</div>
</div>
</div>
<!-- Widget Tag Cloud Ends here -->
</aside>
<!-- Right Side Section End -->
</div>
<section class="cat-box cats-review-box footerSec">
<h2 class="cat-box-title vSec CatArcha">Video
Archives</h2>
<h2 class="cat-box-title CatArchaTitle">Archives</h2>
<div class="cat-box-content">
<div class="reviews-cat">
<div class="CatArchaDiv1">
<div class="CatArchaDiv2">
<ul>
<li>
<a href="https://im4change.in/news-alerts-57/moving-upstream-luni-fellowship.html" target="_blank">
Moving Upstream: Luni – Fellowship </a>
</li>
<li>
<a href="https://im4change.in/news-alerts-57/135-million-indians-exited-multidimensional-poverty-as-per-government-figures-is-that-the-same-as-poverty-reduction.html" target="_blank">
135 Million Indians Exited “Multidimensional" Poverty as per Government... </a>
</li>
<li>
<a href="https://im4change.in/news-alerts-57/explainer-why-are-tomato-prices-on-fire.html" target="_blank">
Explainer: Why are Tomato Prices on Fire? </a>
</li>
<li>
<a href="https://im4change.in/news-alerts-57/nsso-survey-only-39-1-of-all-households-have-drinking-water-within-dwelling-46-7-of-rural-households-use-firewood-for-cooking.html" target="_blank">
NSSO Survey: Only 39.1% of all Households have Drinking... </a>
</li>
<li class="CatArchalLi1">
<a href="https://im4change.in/news-alerts-57"
class="more-link CatArchalAnch1" target="_blank">
More...
</a>
</li>
</ul>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/I51LYnP8BOk/1.jpg"
alt=" Im4Change.org हिंदी वेबसाइट का परिचय. Short Video on im4change.org...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Short-Video-on-im4change-Hindi-website-Inclusive-Media-for-Change" target="_blank">
Im4Change.org हिंदी वेबसाइट का परिचय. Short Video on im4change.org... </a>
</p>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/kNqha-SwfIY/1.jpg"
alt=" "Session 1: Scope of IDEA and AgriStack" in Exploring...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Session-1- Scope-of-IDEA-and-AgriStack-in-Exploring-Digitalisation-in-Agriculture-29-April-2022" target="_blank">
"Session 1: Scope of IDEA and AgriStack" in Exploring... </a>
</p>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/6kIVjlgZItk/1.jpg"
alt=" "Session 2: Farmer Centric Digitalisation in Agriculture" in Exploring...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Session-2-Farmer-Centric-Digitalisation-in-Agriculture-in-Exploring-Digitalisation-in-Agriculture-29-April-2022" target="_blank">
"Session 2: Farmer Centric Digitalisation in Agriculture" in Exploring... </a>
</p>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/2BeHTu0y7xc/1.jpg"
alt=" "Session 3: Future of Digitalisation in Agriculture" in Exploring...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Session-3-Future-of-Digitalisation-in-Agriculture-in-Exploring-Digitalisation-in-Agriculture-29-April-2022" target="_blank">
"Session 3: Future of Digitalisation in Agriculture" in Exploring... </a>
</p>
</div>
<div class="divWidth">
<ul class="divWidthMarg">
<li>
<a href="https://im4change.in/video/Public-Spending-on-Agriculture-in-India-Source-Foundation-for-Agrarian-Studies"
title="Public Spending on Agriculture in India (Source: Foundation for Agrarian Studies)" target="_blank">
Public Spending on Agriculture in India (Source: Foundation for...</a>
</li>
<li>
<a href="https://im4change.in/video/Agrarian-Change-Seminar-Protests-against-the-New-Farm-Laws-in-India-by-Prof-Vikas-Rawal-JNU-Source-Journal-Of-Agrarian-Change"
title="Agrarian Change Seminar: 'Protests against the New Farm Laws in India' by Prof. Vikas Rawal, JNU (Source: Journal Of Agrarian Change) " target="_blank">
Agrarian Change Seminar: 'Protests against the New Farm Laws...</a>
</li>
<li>
<a href="https://im4change.in/video/Webinar-Ramrao-The-Story-of-India-Farm-Crisis-Source-Azim-Premji-University"
title="Webinar: Ramrao - The Story of India's Farm Crisis (Source: Azim Premji University)" target="_blank">
Webinar: Ramrao - The Story of India's Farm Crisis...</a>
</li>
<li>
<a href="https://im4change.in/video/water-and-agricultural-transformation-in-India"
title="Water and Agricultural Transformation in India: A Symbiotic Relationship (Source: IGIDR)" target="_blank">
Water and Agricultural Transformation in India: A Symbiotic Relationship...</a>
</li>
<li class="CatArchalLi1">
<a href="https://im4change.in/videogallery"
class="more-link CatArchalAnch1" target="_blank">
More...
</a>
</li>
</ul>
</div>
</div>
</div>
</div>
</section> </div>
<div class="clear"></div>
<!-- Footer option Starts here -->
<div class="footer-bottom fade-in animated4">
<div class="container">
<div class="social-icons icon_flat">
<p class="SocialMargTop"> Website Developed by <a target="_blank" title="Web Development"
class="wot right"
href="http://www.ravinderkhurana.com/" rel="nofollow">
RAVINDErkHURANA.com</a></p>
</div>
<div class="alignleft">
<a
target="_blank" href="https://im4change.in/objectives-8.html"
class="link"
title="Objectives">Objectives</a> | <a
target="_blank" href="https://im4change.in/about-us-9.html"
class="link" title="About Us">About Us</a> | <a
target="_blank" href="https://im4change.in/media-workshops.php"
class="ucwords">Workshops</a> | <a
target="_blank" href="https://im4change.in/disclaimer/disclaimer-149.html"
title="Disclaimer">Disclaimer</a> </div>
</div>
</div>
<!-- Footer option ends here -->
</div>
<div id="connect">
<a target="_blank"
href="http://www.facebook.com/sharer.php?u=https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575.html"
title="Share on Facebook">
<img src="https://im4change.in/images/Facebook.png?1582080640" alt="share on Facebook" class="ImgBorder"/>
</a><br/>
<a target="_blank"
href="http://twitter.com/share?text=Im4change&url=https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575.html"
title="Share on Twitter">
<img src="https://im4change.in/images/twitter.png?1582080632" alt="Twitter" class="ImgBorder"/> </a>
<br/>
<a href="/feeds" title="RSS Feed" target="_blank">
<img src="https://im4change.in/images/rss.png?1582080632" alt="RSS" class="ImgBorder"/>
</a>
<br/>
<a class="feedback-link" id="feedbackFormLink" href="#">
<img src="https://im4change.in/images/feedback.png?1582080630" alt="Feedback" class="ImgBorder"/>
</a> <br/>
<a href="javascript:function iprl5(){var d=document,z=d.createElement('scr'+'ipt'),b=d.body,l=d.location;try{if(!b)throw(0);d.title='(Saving...) '+d.title;z.setAttribute('src',l.protocol+'//www.instapaper.com/j/WKrH3R7ORD5p?u='+encodeURIComponent(l.href)+'&t='+(new Date().getTime()));b.appendChild(z);}catch(e){alert('Please wait until the page has loaded.');}}iprl5();void(0)"
class="bookmarklet" onclick="return explain_bookmarklet();">
<img src="https://im4change.in/images/read-it-later.png?1582080632" alt="Read Later" class="ImgBorder"/> </a>
</div>
<!-- Feedback form Starts here -->
<div id="feedbackForm" class="overlay_form" class="ImgBorder">
<h2>Contact Form</h2>
<div id="contactform1">
<div id="formleft">
<form id="submitform" action="/contactus.php" method="post">
<input type="hidden" name="submitform" value="submitform"/>
<input type="hidden" name="salt_key" value="a0e0f2c6a0644a70e57ad2c96829709a"/>
<input type="hidden" name="ref" value="feedback"/>
<fieldset>
<label>Name :</label>
<input type="text" name="name" class="tbox" required/>
</fieldset>
<fieldset>
<label>Email :</label>
<input type="text" name="email" class="tbox" required/>
</fieldset>
<fieldset>
<label>Message :</label>
<textarea rows="5" cols="20" name="message" required></textarea>
</fieldset>
<fieldset>
Please enter security code
<div class="clear"></div>
<input type="text" name="vrcode" class="tbox"/>
</fieldset>
<fieldset>
<input type="submit" class="button" value="Submit"/>
<a href="#" id="closefeedbakcformLink">Close</a>
</fieldset>
</form>
</div>
<div class="clearfix"></div>
</div>
</div>
<div id="donate_popup" class="modal" style="max-width: 800px;">
<table width="100%" border="1">
<tr>
<td colspan="2" align="center">
<b>Support im4change</b>
</td>
</tr>
<tr>
<td width="25%" valign="middle">
<img src="https://im4change.in/images/logo2.jpg?1582080632" alt="" width="100%"/> </td>
<td style="padding-left:10px;padding-top:10px;">
<form action="https://im4change.in/donate" method="get">
<table width="100%" cellpadding="2" cellspacing="2">
<tr>
<td width="33%" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
10
</td>
<td width="33%" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
100
</td>
<td width="33%" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
1000
</td>
</tr>
<tr>
<td colspan="3">
</td>
</tr>
<tr>
<td style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
50
</td>
<td style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
500
</td>
<td style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
<input type="text" name="price" placeholder="?" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
</td>
</tr>
<tr>
<td colspan="3">
</td>
</tr>
<tr>
<td colspan="3" align="right">
<input type="button" name="Pay" value="Pay"
style="width: 200px;background-color: rgb(205, 35, 36);color: #ffffff;"/>
</td>
</tr>
</table>
</form>
</td>
</tr>
</table>
</div><script type='text/javascript'>
/* <![CDATA[ */
var tievar = {'go_to': 'Go to...'};
/* ]]> */
</script>
<script src="/js/tie-scripts.js?1575549704"></script><script src="/js/bootstrap.js?1575549704"></script><script src="/js/jquery.modal.min.js?1578284310"></script><script>
$(document).ready(function() {
// tell the autocomplete function to get its data from our php script
$('#s').autocomplete({
source: "/autocomplete"
});
});
</script>
<script src="/vj-main-sw-register.js" async></script>
<script>function init(){var imgDefer=document.getElementsByTagName('img');for(var i=0;i<imgDefer.length;i++){if(imgDefer[i].getAttribute('data-src')){imgDefer[i].setAttribute('src',imgDefer[i].getAttribute('data-src'))}}}
window.onload=init;</script>
</body>
</html>'
}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
$response = object(Cake\Http\Response) {
'status' => (int) 200,
'contentType' => 'text/html',
'headers' => [
'Content-Type' => [
[maximum depth reached]
]
],
'file' => null,
'fileRange' => [],
'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
'cacheDirectives' => [],
'body' => '<!DOCTYPE html>
<!--[if lt IE 7 ]>
<html class="ie ie6" lang='en'> <![endif]-->
<!--[if IE 7 ]>
<html class="ie ie7" lang='en'> <![endif]-->
<!--[if IE 8 ]>
<html class="ie ie8" lang='en'> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!-->
<html lang='en'>
<!--<![endif]-->
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<title>
LATEST NEWS UPDATES | Western warnings-R Ramachandran </title>
<meta name="description" content="
India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines.
AS was only to be expected, the two landmark decisions made by the Indian patent office in recent..."/>
<meta name="keywords" content="Health,patents,medicines"/>
<meta name="news_keywords" content="Health,patents,medicines">
<link rel="alternate" type="application/rss+xml" title="ROR" href="/ror.xml"/>
<link rel="alternate" type="application/rss+xml" title="RSS 2.0" href="/feeds/"/>
<link rel="stylesheet" href="/css/bootstrap.min.css?1697864993"/> <link rel="stylesheet" href="/css/style.css?v=1.1.2"/> <link rel="stylesheet" href="/css/style-inner.css?1577045210"/> <link rel="stylesheet" id="Oswald-css"
href="https://fonts.googleapis.com/css?family=Oswald%3Aregular%2C700&ver=3.8.1" type="text/css"
media="all">
<link rel="stylesheet" href="/css/jquery.modal.min.css?1578285302"/> <script src="/js/jquery-1.10.2.js?1575549704"></script> <script src="/js/jquery-migrate.min.js?1575549704"></script> <link rel="shortcut icon" href="/favicon.ico" title="Favicon">
<link rel="stylesheet" href="/css/jquery-ui.css?1580720609"/> <script src="/js/jquery-ui.js?1575549704"></script> <link rel="preload" as="style" href="https://www.im4change.org/css/custom.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel="preload" as="style" href="https://www.im4change.org/css/jquery.modal.min.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel="preload" as="style" href="https://www.im4change.org/css/jquery-ui.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel="preload" as="style" href="https://www.im4change.org/css/li-scroller.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<!-- <link rel="preload" as="style" href="https://www.im4change.org/css/style.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous"> -->
<link rel="preload" as="style" href="https://www.im4change.org/css/style-inner.css" onload="this.rel='stylesheet'" media="all" crossorigin="anonymous">
<link rel='dns-prefetch' href="//im4change.org/css/custom.css" crossorigin >
<link rel="preload" as="script" href="https://www.im4change.org/js/bootstrap.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery.li-scroller.1.0.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery.modal.min.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery.ui.totop.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery-1.10.2.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery-migrate.min.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/jquery-ui.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/setting.js">
<link rel="preload" as="script" href="https://www.im4change.org/js/tie-scripts.js">
<!--[if IE]>
<script type="text/javascript">jQuery(document).ready(function () {
jQuery(".menu-item").has("ul").children("a").attr("aria-haspopup", "true");
});</script>
<![endif]-->
<!--[if lt IE 9]>
<script src="/js/html5.js"></script>
<script src="/js/selectivizr-min.js"></script>
<![endif]-->
<!--[if IE 8]>
<link rel="stylesheet" type="text/css" media="all" href="/css/ie8.css"/>
<![endif]-->
<meta property="og:title" content="LATEST NEWS UPDATES | Western warnings-R Ramachandran" />
<meta property="og:url" content="https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575.html" />
<meta property="og:type" content="article" />
<meta property="og:description" content="
India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines.
AS was only to be expected, the two landmark decisions made by the Indian patent office in recent..." />
<meta property="og:image" content="" />
<meta property="fb:app_id" content="0" />
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no">
<link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://im4change.in/images/apple1.png">
<link rel="apple-touch-icon-precomposed" sizes="120x120" href="https://im4change.in/images/apple2.png">
<link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://im4change.in/images/apple3.png">
<link rel="apple-touch-icon-precomposed" href="https://im4change.in/images/apple4.png">
<style>
.gsc-results-wrapper-overlay{
top: 38% !important;
height: 50% !important;
}
.gsc-search-button-v2{
border-color: #035588 !important;
background-color: #035588 !important;
}
.gsib_a{
height: 30px !important;
padding: 2px 8px 1px 6px !important;
}
.gsc-search-button-v2{
height: 41px !important;
}
input.gsc-input{
background: none !important;
}
@media only screen and (max-width: 600px) {
.gsc-results-wrapper-overlay{
top: 11% !important;
width: 87% !important;
left: 9% !important;
height: 43% !important;
}
.gsc-search-button-v2{
padding: 10px 10px !important;
}
.gsc-input-box{
height: 28px !important;
}
/* .gsib_a {
padding: 0px 9px 4px 9px !important;
}*/
}
@media only screen and (min-width: 1200px) and (max-width: 1920px) {
table.gsc-search-box{
width: 15% !important;
float: right !important;
margin-top: -118px !important;
}
.gsc-search-button-v2 {
padding: 6px !important;
}
}
</style>
<script>
$(function () {
$("#accordion").accordion({
event: "click hoverintent"
});
});
/*
* hoverIntent | Copyright 2011 Brian Cherne
* http://cherne.net/brian/resources/jquery.hoverIntent.html
* modified by the jQuery UI team
*/
$.event.special.hoverintent = {
setup: function () {
$(this).bind("mouseover", jQuery.event.special.hoverintent.handler);
},
teardown: function () {
$(this).unbind("mouseover", jQuery.event.special.hoverintent.handler);
},
handler: function (event) {
var currentX, currentY, timeout,
args = arguments,
target = $(event.target),
previousX = event.pageX,
previousY = event.pageY;
function track(event) {
currentX = event.pageX;
currentY = event.pageY;
}
;
function clear() {
target
.unbind("mousemove", track)
.unbind("mouseout", clear);
clearTimeout(timeout);
}
function handler() {
var prop,
orig = event;
if ((Math.abs(previousX - currentX) +
Math.abs(previousY - currentY)) < 7) {
clear();
event = $.Event("hoverintent");
for (prop in orig) {
if (!(prop in event)) {
event[prop] = orig[prop];
}
}
// Prevent accessing the original event since the new event
// is fired asynchronously and the old event is no longer
// usable (#6028)
delete event.originalEvent;
target.trigger(event);
} else {
previousX = currentX;
previousY = currentY;
timeout = setTimeout(handler, 100);
}
}
timeout = setTimeout(handler, 100);
target.bind({
mousemove: track,
mouseout: clear
});
}
};
</script>
<script type="text/javascript">
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-472075-3']);
_gaq.push(['_trackPageview']);
(function () {
var ga = document.createElement('script');
ga.type = 'text/javascript';
ga.async = true;
ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
var s = document.getElementsByTagName('script')[0];
s.parentNode.insertBefore(ga, s);
})();
</script>
<link rel="stylesheet" href="/css/custom.css?v=1.16"/> <script src="/js/jquery.ui.totop.js?1575549704"></script> <script src="/js/setting.js?1575549704"></script> <link rel="manifest" href="/manifest.json">
<meta name="theme-color" content="#616163" />
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-status-bar-style" content="black">
<meta name="apple-mobile-web-app-title" content="im4change">
<link rel="apple-touch-icon" href="/icons/logo-192x192.png">
</head>
<body id="top" class="home inner blog">
<div class="background-cover"></div>
<div class="wrapper animated">
<header id="theme-header" class="header_inner" style="position: relative;">
<div class="logo inner_logo" style="left:20px !important">
<a title="Home" href="https://im4change.in/">
<img src="https://im4change.in/images/logo2.jpg?1582080632" class="logo_image" alt="im4change"/> </a>
</div>
<div class="langhindi" style="color: #000;display:none;"
href="https://im4change.in/">
<a class="more-link" href="https://im4change.in/">Home</a>
<a href="https://im4change.in/hindi/" class="langbutton ">हिन्दी</a>
</div>
<nav class="fade-in animated2" id="main-nav">
<div class="container">
<div class="main-menu">
<ul class="menu" id="menu-main">
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children"
style="left: -40px;"><a
target="_blank" href="https://im4change.in/">Home</a>
</li>
<li class="menu-item mega-menu menu-item-type-taxonomy mega-menu menu-item-object-category mega-menu menu-item-has-children parent-list"
style=" margin-left: -40px;"><a href="#">KNOWLEDGE GATEWAY <span class="sub-indicator"></span>
</a>
<div class="mega-menu-block background_menu" style="padding-top:25px;">
<div class="container">
<div class="mega-menu-content">
<div class="mega-menu-item">
<h3><b>Farm Crisis</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/farmers039-suicides-14.html"
class="left postionrel">Farm Suicides </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/unemployment-30.html"
class="left postionrel">Unemployment </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/rural-distress-70.html"
class="left postionrel">Rural distress </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/migration-34.html"
class="left postionrel">Migration </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/key-facts-72.html"
class="left postionrel">Key Facts </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/farm-crisis/debt-trap-15.html"
class="left postionrel">Debt Trap </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Empowerment</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/union-budget-73.html"
class="left postionrel">Union Budget And Other Economic Policies </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/forest-and-tribal-rights-61.html"
class="left postionrel">Forest and Tribal Rights </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-education-60.html"
class="left postionrel">Right to Education </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-food-59.html"
class="left postionrel">Right to Food </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/displacement-3279.html"
class="left postionrel">Displacement </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-work-mg-nrega-39.html"
class="left postionrel">Right to Work (MG-NREGA) </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/gender-3280.html"
class="left postionrel">GENDER </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/right-to-information-58.html"
class="left postionrel">Right to Information </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/empowerment/social-audit-48.html"
class="left postionrel">Social Audit </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Hunger / HDI</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/poverty-and-inequality-20499.html"
class="left postionrel">Poverty and inequality </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/malnutrition-41.html"
class="left postionrel">Malnutrition </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/public-health-51.html"
class="left postionrel">Public Health </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/education-50.html"
class="left postionrel">Education </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/hunger-overview-40.html"
class="left postionrel">Hunger Overview </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/hdi-overview-45.html"
class="left postionrel">HDI Overview </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/pds-ration-food-security-42.html"
class="left postionrel">PDS/ Ration/ Food Security </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/sdgs-113.html"
class="left postionrel">SDGs </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/hunger-hdi/mid-day-meal-scheme-mdms-53.html"
class="left postionrel">Mid Day Meal Scheme (MDMS) </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Environment</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/environment/time-bomb-ticking-52.html"
class="left postionrel">Time Bomb Ticking </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/environment/water-and-sanitation-55.html"
class="left postionrel">Water and Sanitation </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/environment/impact-on-agriculture-54.html"
class="left postionrel">Impact on Agriculture </a>
</p>
</div>
<div class="mega-menu-item">
<h3><b>Law & Justice</b></h3>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/social-justice-20500.html"
class="left postionrel">Social Justice </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/access-to-justice-47.html"
class="left postionrel">Access to Justice </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/human-rights-56.html"
class="left postionrel">Human Rights </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/corruption-35.html"
class="left postionrel">Corruption </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/general-insecurity-46.html"
class="left postionrel">General Insecurity </a>
</p>
<p style="padding-left:5px;">
<a target="_blank" href="https://im4change.in/law-justice/disaster-relief-49.html"
class="left postionrel">Disaster & Relief </a>
</p>
</div>
</div>
</div>
</div>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page "><a target="_blank" href="https://im4change.in/nceus_reports.php">NCEUS reports</a>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children parent-list ">
<a target="_blank" href="https://im4change.in/about-us-9.html">About Us <span
class="sub-indicator"></span></a>
<ul class="sub-menu aboutmenu">
<li class="menu-item menu-item-type-post_type menu-item-object-page"><a
target="_blank" href="https://im4change.in/objectives-8.html">Objectives</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page"><a
target="_blank" href="https://im4change.in/contactus.php">Contact
Us</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page"><a
target="_blank" href="https://im4change.in/about-us-9.html">About
Us</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children ">
<a target="_blank" href="https://im4change.in/fellowships.php" title="Fellowships">Fellowships</a>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children "><a
target="_blank" href="https://im4change.in/media-workshops.php">Workshops</a>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children "><a
target="_blank" href="https://im4change.in/research.php">Research</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children "><a
target="_blank" href="https://im4change.in/links-64">Partners</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children"
id="menu-item-539"><a target="_blank" href="https://im4change.in/hindi/"
class="langbutton langlinkfont17">हिन्दी</a></li>
</ul>
</div> </div>
<!-- <div style="float: right;">
<script async src="https://cse.google.com/cse.js?cx=18b4f2e0f11bed3dd"></script>
<div class="gcse-search"></div>
</div> -->
<div class="search-block" style=" margin-left: 8px; margin-right: 7px;">
<form method="get" id="searchform" name="searchform"
action="https://im4change.in/search"
onsubmit="return searchvalidate();">
<button class="search-button" type="submit" value="Search"></button>
<input type="text" id="s" name="qryStr" value=""
onfocus="if (this.value == 'Search...') {this.value = '';}"
onblur="if (this.value == '') {this.value = 'Search...';}">
</form>
</div>
</nav>
</header>
<div class="container">
<div id="main-content" class=" main1 container fade-in animated3 sidebar-narrow-left">
<div class="content-wrap">
<div class="content" style="width: 900px;min-height: 500px;">
<section class="cat-box recent-box innerCatRecent">
<h1 class="cat-box-title">Western warnings-R Ramachandran</h1>
<a href="JavaScript:void(0);" onclick="return shareArticle(14451);">
<img src="https://im4change.in/images/email.png?1582080630" border="0" width="24" align="right" alt="Share this article"/> </a>
<a href="https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575/print"
rel="nofollow">
<img src="https://im4change.in/images/icon-print.png?1582080630" border="0" width="24" align="right" alt="Share this article"/>
</a>
</section>
<section class="recent-box innerCatRecent">
<small class="pb-1"><span class="dateIcn">
<img src="https://im4change.in/images/published.svg?1582080666" alt="published"/>
Published on</span><span class="text-date"> Apr 20, 2012</span>
<span
class="dateIcn">
<img src="https://im4change.in/images/modified.svg?1582080666" alt="modified"/> Modified on </span><span class="text-date"> Apr 20, 2012</span>
</small>
</section>
<div class="clear"></div>
<div style="padding-top: 10px;">
<div class="innerLineHeight">
<div class="middleContent innerInput latest-news-updates">
<table>
<tr>
<td>
<div>
<br /><div align="justify"><em>India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines. <br /></em><br />AS was only to be expected, the two landmark decisions made by the Indian patent office in recent times concerning pharmaceutical patent cases have not gone down well with the multinational drug industry. First, there was the rejection in 2006 of the patent application by the Swiss multinational Novartis for imatinib mesylate (sold under the brand name of Glivec, or Gleevec), its incrementally modified drug for leukaemia, or blood cancer. Then, on March 12, 2012, the Indian generic drug company Natco Pharma Ltd was granted a manufacturing licence to produce a generic version of the patented liver and kidney cancer drug sorafenib tosylate of the German multinational company (MNC) Bayer (brand name Nexavar) through the first-ever invocation of the compulsory licence (CL) provision in the Indian Patents Act, 1970 (as amended in 2005). The CL was granted to ensure affordability of the drug to Indian cancer patients. Natco will now produce the drug at a price that will be 97 per cent lower than Bayer's even after paying 6 per cent royalty on net sales to Bayer.<br /><br />Bayer will most likely appeal against the order. Novartis challenged the patent office's rejection of its patent application first at the Intellectual Property Appellate Board (IPAB) and subsequently in the Madras High Court. Both upheld the Patent Controller's decision and rejected Novartis' appeals against the Indian government. Now the company has appealed to the Supreme Court. The first hearing is slated for July 10. These two cases have demonstrated how flexibilities available in the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement (for patent protection) of the World Trade Organisation (WTO) can be successfully used to serve public health interests in developing countries over the interests of the private monopoly of profit-driven drug MNCs. The flexibilities in the TRIPS Agreement allow governments to decide what type of “innovation” is patentable. The criteria of “novelty”, “inventive step”, and “industrial applicability” are not defined in the agreement and are left for individual governments to determine within existing national legislation and circumstances. These are also, therefore, test cases for the Indian judiciary, and if these orders can be sustained in the face of imminent legal battles, they will serve as important precedents for exploiting the full power of the Indian Patents Act, while conforming to the WTO's intellectual property rights (IPR) regime, to ensure the Indian public access to health care it can afford.<br /><br />Drug majors around the world, American companies in particular, which have, of course, been watching the Novartis case anxiously for the past five years, have been further jolted by the latest decision on Nexavar. The president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), John Castellani, issued the following statement immediately after India granted the CL for the indigenous production of Nexavar's generic version:<br /><br />“While India has not routinely issued CLs, PhRMA believes it is not an appropriate tool even if granting CLs may be a legal option.… Legitimate health emergencies that require making exceptions to IPRs can, and should, be accommodated under the international framework, but only after exhausting all other efforts and under extraordinary circumstances…. [O]ne aspect that is particularly troublesome is the contention that ‘working' a patent requires a company to manufacture within India. It is our firm belief that this is fully at odds with India's TRIPS commitments (as well as broader WTO obligations), and distorts what was intended as a public health exception into an industrial policy…. CLs cannot solve India's larger problems regarding access to medicines and health care.”<br /><br />The PhRMA's contentions are patently wrong as the decision is in full compliance with the Doha “Declaration on the TRIPS Agreement and Public Health” of November 2001 and Article 31 of TRIPS. But the protest was conveyed more brazenly to the Indian government when the visiting United States Commerce Secretary, John Bryson, raised the issue of India granting a CL to Natco in his meeting with Commerce and Industry Minister Anand Sharma on March 25. Bryson apparently said that any dilution of the international patent regime was a cause for deep concern for the U.S. This was clearly an unwarranted remark on the part of the U.S. official because if there was any perceived violation of TRIPS, the correct forum for the U.S. to address the issue was the WTO.<br /><br />The U.S. has instituted an internal mechanism under its trade policy to deal with what it perceives as trade barriers in its trading-partner countries on the basis of an annual assessment in what is called the “Special 301 Report” by the office of the U.S. Trade Representative (USTR). India has consistently been placed in the “Priority Watch List” of the report. Following the court's rejection of Novartis' appeal in 2009, the 2010 report included a response of the USTR to the Indian decision.<br /><br />The report said: “The United States continues to urge India to improve its IPR regime by providing stronger protection for patents. One concern in this regard is a provision in India's Patent Law that prohibits patents on certain chemical forms absent a showing of increased efficacy. While the full import of this provision remains unclear, it appears to limit the patentability of potentially beneficial innovations, such as temperature-stable forms of a drug or new means of drug delivery” (emphasis added, throughout).<br /><br />The wording clearly reflects the U.S.' objection to the Indian patent office not granting a new patent for a new chemical form of a patented drug that the manufacturer claims had increased bioabsorption but for which there was no proven increased therapeutic efficacy. The 2011 report, too, essentially repeated the same objection to the restricted scope of patentability of drugs under the Patents Act. The administration's objection to the Bayer-Nexavar case is bound to be reflected in the 2012 report, given that the PhRMA has already voiced its protest. Drugs are big business around the world for the U.S. industry, and the PhRMA, which acts as the prime lobby group for the U.S. drug industry, naturally has a major influence on the contents of the Special 301 Report.<br /><br />In its submission to the USTR on the 2012 Special 301 Report, the PhRMA said the following with regard to the patentability criteria exercised by the Indian patent office in the Novartis case: “Some of the standards for patentability in India are not transparent and are inconsistent with the TRIPS Agreement. For example, Section 3(d) of the [Indian] Patents Act… creates additional hurdles to the grant of certain chemical compound patents, and appears to be applied only to pharmaceuticals. Under this provision, salts, esters, ethers, polymorphs, and other derivatives of known substances are presumed to be the same substance as the original chemical and thus not patentable, unless it can be shown that they differ significantly in properties with regard to efficacy. These additional requirements for patentability beyond novelty, commercial applicability and non-obviousness are inconsistent with the TRIPS Agreement.... Article 27 of the TRIPS Agreement provides a non-extendable list of the types of subject matter that can be excluded from patent coverage. This list does not include ‘new forms of known substances lacking enhanced efficacy', as excluded by Section 3(d) of the Indian law.” This argument is misplaced because the rejection is on the grounds of the new drug not meeting the basic criterion of patentability, which is novelty, meaning that it should be a new compound and should involve an inventive step. Novartis was seeking a patent for just the beta crystalline variant of a patented amorphous molecule, claiming merely better bioavailability. Such an incremental modification is not something that involves inventiveness, the court contended.<br /><br />On the issue of CLs, which is another key issue of concern to the PhRMA, its submission, made in February, a month before the decision on the Bayer case was pronounced, stated: “Domestic companies have started filing CL applications with the Indian patent office, apparently prompted in part by government statements suggesting that CLs may be a means for ensuring availability and affordability of drugs worldwide…. At a minimum, India should ensure that the CL provisions comply with TRIPS by... eliminating price as a trigger to CL.” (Section 84(1) (b) of the Indian Patents Act permits a CL if the patented invention is not available to the public at a “reasonably affordable price”.)<br /><br />This again is a misplaced objection because a country is free to decide on the reasons for granting a CL as is clear from the Doha Declaration, which says: “Each member has the right to grant compulsory licences and the freedom to determine the grounds upon which such licences are granted; Each member has the right to determine what constitutes a national emergency or other circumstances of extreme urgency, it being understood that public health crises, including those relating to HIV/AIDS, tuberculosis, malaria and other epidemics, can represent a national emergency or other circumstances of extreme urgency.” The patent office exercised the freedom of granting the CL to Natco on the issue of affordability, given that Natco's generic drug will cost Rs.8,800 a month as against Bayer's Rs.2.8 lakh a month and that cancer treatment is lifelong.<br /><br />Retaliation following the listing of a country on the watch list includes the U.S. initiating dispute settlement mechanisms at international trade forums such as the WTO, elimination of preferential tariff preferences under bilateral trade agreements, if any, and even unilateral trade sanctions against the named country. Bryson's remarks are perhaps a veiled threat of such action against India since there are many such pharmaceutical patent cases pending in Indian courts for which these cases could become precedents, affecting the potentially huge market of American MNCs.<br />Trade policy forum<br /><br />There exists a bilateral engagement between India and the U.S. under what is called the U.S.-India Trade Policy Forum (TPF) formed in 2005 alongside the various India-U.S. agreements that came into being, including the nuclear deal. The TPF has five focus groups: agriculture, investment, innovation and creativity (IPR), services, and tariff and non-tariff barriers. Under the TPF, a framework for cooperation and trade was signed two years ago.<br /><br />Although its proposed work plan does not specifically mention IPR, it does include a group focussing on tariff and non-tariff barriers, which is aimed at “promoting policies to expand market access, including adopting transparent, WTO-policies….” It is quite likely that this bilateral forum will begin to be used by the U.S. to bring on pressure on contentious issues concerning IPR.<br /><br />Interestingly, the scheduled meeting of the TPF has been postponed twice by the U.S. since October, the most recent being the meeting of the Commerce Minister with USTR Ron Kirk in January. According to media reports, this is because of insufficient progress achieved on the various issues, increasing market access to U.S. companies, in particular. Clearly, the U.S. will increase pressure on the IPR issue in the wake of the recent CL decision at the next meeting of the TPF, which has been pushed to mid-2012. The Indian government would do well to guard against that. Health-care activists and IPR experts have voiced similar concern over the proposed India-European Union (E.U.) Free Trade Agreement (FTA).<br /><br />According to reports, the 27-nation bloc has been pressing India to agree to an IPR regime over and above TRIPS. This demand is related to the area of pharmaceuticals, particularly after the Novartis decision, and this demand in all likelihood will become stronger now. Recently, however, Minister Anand Sharma assured a visiting UNAIDS (Joint United Nations Programme on HIV/AIDS) executive that India would reject efforts to include a “data exclusivity” clause in bilateral agreements and affirmed the Indian government's full commitment to ensure quality generic medicines through compulsory licensing and other TRIPS flexibilities. Notwithstanding this, in a recent article in The Guardian, Philippe Douste-Blazy, U.N. Special Adviser on Innovative Financing for Development, and Denis Broun, Executive Director of Unitaid, an international facility for the purchase of drugs for HIV/AIDS, malaria and tuberculosis hosted by the World Health Organisation in Geneva, wrote: “If stringent patent and border measures are agreed on at the E.U.-India FTA summit, patients in poor countries will no longer have access to cheap generic medicines; India's role as the ‘pharmacy of the South' could well come to an end.”<br /><br />The U.S. has already begun to exert such pressures and force countries in some other parts of the world into accepting IPR protection standards that are stronger than the TRIPS regime. Under the Trans-Pacific Partnership, a multilateral free trade agreement between the U.S. and the countries of the Asia-Pacific region that seeks to further liberalise these economies, the U.S. intends to broaden the scope of patentability by eroding the flexibility afforded by TRIPS by requesting TPP partner countries to pass new laws and rules that severely limit the ability of each country to define what is “patentable”. The nine countries currently negotiating the TPP are Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the U.S. and Vietnam. Japan and South Korea are intending to join the group shortly.<br /><br />A leaked draft of the chapter on IPR in a U.S.-negotiating TPP text, which reflects the U.S. position on this multilateral arrangement, indicates that the U.S. is demanding aggressive IPR provisions that go beyond what international trade law (under TRIPS) requires: “Each Party,” says the draft U.S. proposal, “ shall confirm that: patents shall be available for any new forms, uses, or methods of using a known product; and a new form, use, or method of using a known product may satisfy the criteria for patentability, even if such invention does not result in the enhancement of the known efficacy of that product.” This is the “patent evergreening” technique that Novartis tried to employ, which the Indian patent office rejected. Evergreening of a patent allows pharmaceutical companies to obtain or extend monopoly protection for old drugs simply by making minor modifications to existing formulae. The international organisation Medecins Sans Frontieres (Doctors Without Borders), which provides affordable health care around the world, points out: “Evergreening significantly delays the arrival of more affordable generic medicines into the market.” The TPP draft text further wants plants and animals and diagnostic, therapeutic and surgical methods for the treatment of humans or animals, which are explicitly ruled by TRIPS to be non-patentable, to be patentable.<br /><br />In addition, another leaked document pertaining to the TPP seeks to eliminate the process of pre-grant opposition to a patent application, which is an important tool to prevent patent applications based on weak or erroneous information. The U.S. proposal, if accepted, would allow opposition only after the patent is granted.<br /><br />Although this does not directly or immediately affect the Indian situation, it does portend ominous moves on this front by the U.S. on India as well. This is evident from the remarks Ron Kirk made recently: “U.S. involvement in the TPP is predicated on the expansion of the agreement to include more economies in the Asia-Pacific region…[and] should set the standard for 21st century trade agreements going forward.”<br /><br />It, therefore, stands to reason that the norms that emerge from the TPP negotiations will serve as the template for future U.S. trade agreements across the world. Using the leverage of the many countries in the TPP fold, and perhaps in other bilateral agreements, which accept this new enlarged premise for patentability, the WTO, too, eventually might come under pressure to change its rules of dispute settlement and arbitration. The implications of this are that IPR regimes, in particular the strict patentability criteria for drugs, of countries such as India, which have the responsibility of extending affordable health care to millions, will increasingly come under severe attack from the U.S. and the E.U., where nearly all the big drug multinationals operate and profit at the cost of the suffering poor of developing countries.</div>
</div>
</td>
</tr>
</table>
</div>
</div>
</div>
<div class="clear"></div>
<br><a href="http://www.frontlineonnet.com/stories/20120504290801800.htm" class="re" target="_blank">Frontline, Volume 29, Issue 08, 21 April-04 May, 2012, http://www.frontlineonnet.com/stories/20120504290801800.htm</a><div class="clear"></div>
<div style="padding-top: 18px;">
<p class="post-tag">Tagged with:
<a class="tagcloud5"
href="https://im4change.in/search?qryStr=Health"
title="Health">
Health </a>
<a class="tagcloud5"
href="https://im4change.in/search?qryStr=patents"
title="patents">
patents </a>
<a class="tagcloud5"
href="https://im4change.in/search?qryStr=medicines"
title="medicines">
medicines </a>
</p>
</div>
<div class="clear"></div>
<br><br>
<div class="widget-top">
<h4>Related Articles</h4>
<div class="stripe-line"></div>
</div>
<div class="widget-container">
<ul id="recentcomments">
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/fifth-report-from-gambia-implicates-indian-drug-maker-for-contaminated-syrups-banjot-kaur.html"
title="Fifth Report From Gambia Implicates Indian Drug Maker for Contaminated Syrups - Banjot Kaur">
Fifth Report From Gambia Implicates Indian Drug Maker for Contaminated Syrups - Banjot Kaur </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/india-may-have-seen-steepest-dip-in-multidimensional-poverty-among-110-nations-as-per-undp-data-nikhil-rampal.html"
title="India may have seen steepest dip in multidimensional poverty among 110 nations as per UNDP data - Nikhil Rampal">
India may have seen steepest dip in multidimensional poverty among 110 nations as per UNDP data - Nikhil Rampal </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/health-among-top-three-priorities-for-indian-voters-after-jobs-and-education-survey-shows-oliver-heath-jyoti-mishra-louise-tillin-sandhya-venkateswaran.html"
title="Health among top three priorities for Indian voters after jobs and education, survey shows - Oliver Heath, Jyoti Mishra, Louise Tillin & Sandhya Venkateswaran">
Health among top three priorities for Indian voters after jobs and education, survey shows - Oliver Heath, Jyoti Mishra, Louise Tillin & Sandhya Venkateswaran </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/prevalence-of-zero-food-among-infants-and-young-children-in-india-patterns-of-change-across-the-states-and-union-territories-of-india-1993-2021-the-lancet.html"
title="Prevalence of Zero-Food among infants and young children in India - The Lancet ">
Prevalence of Zero-Food among infants and young children in India - The Lancet </a>
</li>
<li class="recentcomments">
<a href="https://im4change.in/latest-news-updates/india-s-sustainability-goals-at-risk-because-of-extreme-heatwaves-carbon-copy.html"
title="India's Sustainability Goals at Risk Because of Extreme Heatwaves - Carbon Copy">
India's Sustainability Goals at Risk Because of Extreme Heatwaves - Carbon Copy </a>
</li>
</ul>
</div>
<div class="comment-respond" id="respond">
<a name="commentbox"> </a>
<h3 class="comment-reply-title" id="reply-title">Write Comments</h3>
<form method="post" accept-charset="utf-8" role="form" action="/latest-news-updates/western-warnings-r-ramachandran-14575.html"><div style="display:none;"><input type="hidden" name="_method" value="POST"/></div> <form class="comment-form" id="commentform" method="post" action="#commentbox" onSubmit="return validate()"
name="cmtform">
<input type="hidden" name="cmttype" value="articlecmt"/>
<input type="hidden" name="article_id" value="14451"/>
<p class="comment-notes">Your email address will not be published. Required fields are marked <span
class="required">*</span></p>
<p class="comment-form-author">
<label for="commenterName">Name</label>
<span class="required">*</span>
<input type="text" aria-required="true" size="30"
value=""
name="commenterName" id="commenterName" required="true">
</p>
<p class="comment-form-email">
<label for="commenterEmail">Email</label> <span class="required">*</span>
<input aria-required="true" size="30" name="commenterEmail" id="commenterEmail" type="email"
value=""
required="true">
</p>
<p class="comment-form-contact">
<label for="commenterPh">Contact No.</label>
<input type="text" size="30"
value=""
name="commenterPh" id="commenterPh">
</p>
<p class="comment-form-comment">
<label for="comment">Comment</label>
<textarea aria-required="true" required="true" rows="8" cols="45" name="comment"
id="comment"></textarea>
</p>
<p class="comment-form-comment">
<label for="comment">Type the characters you see in the image below <span class="required">*</span><br><img
class="captchaImg"
src="https://im4change.in/securimage_show_art.php?tk=462617871" alt="captcha"/>
</label>
</p>
<input type="text" name="vrcode" required="true"/>
<p class="form-submit" style="width: 200px;">
<input type="submit" value="Post Comment" id="submit" name="submit">
</p></form>
</div>
<style>
.ui-widget-content {
height: auto !important;
}
</style>
<div id="share-modal"></div>
<style>
.middleContent a{
background-color: rgba(108,172,228,.2);
}
.middleContent a:hover{
background-color: #418fde;
border-color: #418fde;
color: #000;
}
</style>
<script>
function shareArticle(article_id) {
var options = {
modal: true,
height: 'auto',
width: 600 + 'px'
};
$('#share-modal').html("");
$('#share-modal').load('https://im4change.in/share_article?article_id=' + article_id).dialog(options).dialog('open');
}
function postShare() {
var param = 'article_id=' + $("#article_id").val();
param = param + '&y_name=' + $("#y_name").val();
param = param + '&y_email=' + $("#y_email").val();
param = param + '&f_name=' + $("#f_name").val();
param = param + '&f_email=' + $("#f_email").val();
param = param + '&y_msg=' + $("#y_msg").val();
$.ajax({
type: "POST",
url: 'https://im4change.in/post_share_article',
data: param,
success: function (response) {
$('#share-modal').html("Thank You, Your message posted to ");
}
});
return false;
}
</script> </div>
</div>
<!-- Right Side Section Start -->
<!-- MAP Section START -->
<aside class="sidebar indexMarg">
<div class="ad-cell">
<a href="https://im4change.in/statemap.php" title="">
<img src="https://im4change.in/images/map_new_version.png?1582080666" alt="India State Map" class="indiamap" width="232" height="252"/> </a>
<div class="rightmapbox">
<div id="sideOne" class="docltitle"><a href="https://im4change.in/state-report/india/36" target="_blank">DOCUMENTS/
REPORTS</a></div>
<div id="sideTwo" class="statetitle"><a href="https://im4change.in/states.php"target="_blank">STATE DATA/
HDRs.</a></div>
</div>
<div class="widget widgePadTop"></div>
</div>
</aside>
<!-- MAP Section END -->
<aside class="sidebar sidePadbottom">
<div class="rightsmlbox1" >
<a href="https://im4change.in/knowledge_gateway" target="_blank" style="color: #035588;
font-size: 17px;">
KNOWLEDGE GATEWAY
</a>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title">
<a href="https://im4change.in/newsletter" target="_blank">
NEWSLETTER
</a>
</p>
</div>
</div>
<div class="rightsmlbox1" style="height: 325px;">
<div>
<p class="rightsmlbox1_title">
Interview with Prof. Ravi Srivastava
</p>
<p class="rightsmlbox1_title">
<a href="https://im4change.in/video/interview-with-prof-ravi-srivastava-on-current-economic-crisis">
<img width="250" height="200" src="/images/interview_video_home.jpg" alt="Interview with Prof. Ravi Srivastava"/>
</a>
<!--
<iframe width="250" height="200" src="https://www.youtube.com/embed/MmaTlntk-wc" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen=""></iframe>-->
</p>
<a href="https://im4change.in/videogallery" class="more-link CatArchalAnch1" target="_blank">
More videos
</a>
</div>
</div>
<div class="rightsmlbox1">
<div>
<!--div id="sstory" class="rightboxicons"></div--->
<p class="rightsmlbox1_title"><a href="https://im4change.in/list-success-stories" target="_blank">Success Stories</a></p>
</div>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title"><a
href="https://im4change.in/interviews" target="_blank">Interviews</a>
</p>
</div>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title"><a href="https://www.commoncause.in/page.php?id=10" >Donate</a></p>
</div>
</div>
<div class="rightsmlbox1">
<div>
<p class="rightsmlbox1_title"><a
href="https://im4change.in/marquee"
class="isf_link more-link" title="India Focus?" style="border: 4px solid #fdd922;width: 90%;background-color: #fdd922;text-align: center;color: #000000;font-size:18px" target="_blank">India Focus</a></p> </div>
</div>
<div class="rightsmlbox1" style="height: 104px !important;">
<a href="https://im4change.in/quarterly_reports.php" target="_blank">
Quarterly Reports on Effect of Economic Slowdown on Employment in India (2008 - 2015)
</a>
</div>
<!-- <div class="rightsmlbox1">
<a href="https://play.google.com/store/apps/details?id=com.im4.im4change" target="_blank">
</a></div> -->
<!-- <section class="cat-box recent-box secMarg">
<h2 class="cat-box-title">Most Visited</h2>
</section> -->
<!-- accordion Starts here -->
<!-- <div id="accordion" class="accordMarg">
</div> -->
<!-- accordion ends here -->
<!-- Widget Tag Cloud Starts here -->
<div id="tag_cloud-2" class="widget widget_tag_cloud">
<section class="cat-box recent-box secMarg">
<h2 class="cat-box-title">MOST VISITED TAGS</h2>
</section>
<div class="widget-top wiPdTp">
<div class="stripe-line"></div>
</div>
<div class="widget-container">
<div class="tagcloud">
<a href="https://im4change.in/search?qryStr=Agriculture"
target="_blank" class="tag-link-4 font4">Agriculture</a>
<a href="https://im4change.in/search?qryStr=Food Security"
target="_blank" class="tag-link-4 font4">Food Security</a>
<a href="https://im4change.in/search?qryStr=Law and Justice"
target="_blank" class="tag-link-4 font4">Law and Justice</a>
<a href="https://im4change.in/search?qryStr=Health"
target="_blank" class="tag-link-4 font4">Health</a>
<a href="https://im4change.in/search?qryStr=Right to Food"
target="_blank" class="tag-link-4 font4">Right to Food</a>
<a href="https://im4change.in/search?qryStr=Corruption"
target="_blank" class="tag-link-4 font4">Corruption</a>
<a href="https://im4change.in/search?qryStr=farming"
target="_blank" class="tag-link-4 font4">farming</a>
<a href="https://im4change.in/search?qryStr=Environment"
target="_blank" class="tag-link-4 font4">Environment</a>
<a href="https://im4change.in/search?qryStr=Right to Information"
target="_blank" class="tag-link-4 font4">Right to Information</a>
<a href="https://im4change.in/search?qryStr=NREGS"
target="_blank" class="tag-link-4 font4">NREGS</a>
<a href="https://im4change.in/search?qryStr=Human Rights"
target="_blank" class="tag-link-4 font4">Human Rights</a>
<a href="https://im4change.in/search?qryStr=Governance"
target="_blank" class="tag-link-4 font4">Governance</a>
<a href="https://im4change.in/search?qryStr=PDS"
target="_blank" class="tag-link-4 font4">PDS</a>
<a href="https://im4change.in/search?qryStr=COVID-19"
target="_blank" class="tag-link-4 font4">COVID-19</a>
<a href="https://im4change.in/search?qryStr=Land Acquisition"
target="_blank" class="tag-link-4 font4">Land Acquisition</a>
<a href="https://im4change.in/search?qryStr=mgnrega"
target="_blank" class="tag-link-4 font4">mgnrega</a>
<a href="https://im4change.in/search?qryStr=Farmers"
target="_blank" class="tag-link-4 font4">Farmers</a>
<a href="https://im4change.in/search?qryStr=transparency"
target="_blank" class="tag-link-4 font4">transparency</a>
<a href="https://im4change.in/search?qryStr=Gender"
target="_blank" class="tag-link-4 font4">Gender</a>
<a href="https://im4change.in/search?qryStr=Poverty"
target="_blank" class="tag-link-4 font4">Poverty</a>
<a href="https://im4change.in/search?qryStr=Farm Laws" target="_blank" class="tag-link-4 font4">Farm Laws
</a>
<a href="https://im4change.in/search?qryStr=Citizenship Amendment Act" target="_blank" class="tag-link-4 font4">Citizenship Amendment Act
</a>
<a href="https://im4change.in/search?qryStr=CAA NPR NRIC" target="_blank" class="tag-link-4 font4">CAA NPR NRIC
</a>
<a href="https://im4change.in/search?qryStr=Job Losses" target="_blank" class="tag-link-4 font4">Job Losses
</a>
<a href="https://im4change.in/search?qryStr=Migrant Workers" target="_blank" class="tag-link-4 font4">Migrant Workers
</a>
<a href="https://im4change.in/search?qryStr=Unemployment" target="_blank" class="tag-link-4 font4">Unemployment
</a>
<a href="https://im4change.in/search?qryStr=PMGKAY" target="_blank" class="tag-link-4 font4">PMGKAY
</a>
<a href="https://im4change.in/search?qryStr=PM-KISAN" target="_blank" class="tag-link-4 font4">PM-KISAN
</a>
<a href="https://im4change.in/search?qryStr=PM-CARES" target="_blank" class="tag-link-4 font4">PM-CARES
</a>
<a href="https://im4change.in/search?qryStr=LFPR" target="_blank" class="tag-link-4 font4">LFPR
</a>
</div>
</div>
</div>
<!-- Widget Tag Cloud Ends here -->
</aside>
<!-- Right Side Section End -->
</div>
<section class="cat-box cats-review-box footerSec">
<h2 class="cat-box-title vSec CatArcha">Video
Archives</h2>
<h2 class="cat-box-title CatArchaTitle">Archives</h2>
<div class="cat-box-content">
<div class="reviews-cat">
<div class="CatArchaDiv1">
<div class="CatArchaDiv2">
<ul>
<li>
<a href="https://im4change.in/news-alerts-57/moving-upstream-luni-fellowship.html" target="_blank">
Moving Upstream: Luni – Fellowship </a>
</li>
<li>
<a href="https://im4change.in/news-alerts-57/135-million-indians-exited-multidimensional-poverty-as-per-government-figures-is-that-the-same-as-poverty-reduction.html" target="_blank">
135 Million Indians Exited “Multidimensional" Poverty as per Government... </a>
</li>
<li>
<a href="https://im4change.in/news-alerts-57/explainer-why-are-tomato-prices-on-fire.html" target="_blank">
Explainer: Why are Tomato Prices on Fire? </a>
</li>
<li>
<a href="https://im4change.in/news-alerts-57/nsso-survey-only-39-1-of-all-households-have-drinking-water-within-dwelling-46-7-of-rural-households-use-firewood-for-cooking.html" target="_blank">
NSSO Survey: Only 39.1% of all Households have Drinking... </a>
</li>
<li class="CatArchalLi1">
<a href="https://im4change.in/news-alerts-57"
class="more-link CatArchalAnch1" target="_blank">
More...
</a>
</li>
</ul>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/I51LYnP8BOk/1.jpg"
alt=" Im4Change.org हिंदी वेबसाइट का परिचय. Short Video on im4change.org...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Short-Video-on-im4change-Hindi-website-Inclusive-Media-for-Change" target="_blank">
Im4Change.org हिंदी वेबसाइट का परिचय. Short Video on im4change.org... </a>
</p>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/kNqha-SwfIY/1.jpg"
alt=" "Session 1: Scope of IDEA and AgriStack" in Exploring...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Session-1- Scope-of-IDEA-and-AgriStack-in-Exploring-Digitalisation-in-Agriculture-29-April-2022" target="_blank">
"Session 1: Scope of IDEA and AgriStack" in Exploring... </a>
</p>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/6kIVjlgZItk/1.jpg"
alt=" "Session 2: Farmer Centric Digitalisation in Agriculture" in Exploring...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Session-2-Farmer-Centric-Digitalisation-in-Agriculture-in-Exploring-Digitalisation-in-Agriculture-29-April-2022" target="_blank">
"Session 2: Farmer Centric Digitalisation in Agriculture" in Exploring... </a>
</p>
</div>
<div class="CatArchaWidth">
<img class="CatArchaImg"
src="https://img.youtube.com/vi/2BeHTu0y7xc/1.jpg"
alt=" "Session 3: Future of Digitalisation in Agriculture" in Exploring...">
<p class="CatArchaPPad">
<a href="https://im4change.in/video/Session-3-Future-of-Digitalisation-in-Agriculture-in-Exploring-Digitalisation-in-Agriculture-29-April-2022" target="_blank">
"Session 3: Future of Digitalisation in Agriculture" in Exploring... </a>
</p>
</div>
<div class="divWidth">
<ul class="divWidthMarg">
<li>
<a href="https://im4change.in/video/Public-Spending-on-Agriculture-in-India-Source-Foundation-for-Agrarian-Studies"
title="Public Spending on Agriculture in India (Source: Foundation for Agrarian Studies)" target="_blank">
Public Spending on Agriculture in India (Source: Foundation for...</a>
</li>
<li>
<a href="https://im4change.in/video/Agrarian-Change-Seminar-Protests-against-the-New-Farm-Laws-in-India-by-Prof-Vikas-Rawal-JNU-Source-Journal-Of-Agrarian-Change"
title="Agrarian Change Seminar: 'Protests against the New Farm Laws in India' by Prof. Vikas Rawal, JNU (Source: Journal Of Agrarian Change) " target="_blank">
Agrarian Change Seminar: 'Protests against the New Farm Laws...</a>
</li>
<li>
<a href="https://im4change.in/video/Webinar-Ramrao-The-Story-of-India-Farm-Crisis-Source-Azim-Premji-University"
title="Webinar: Ramrao - The Story of India's Farm Crisis (Source: Azim Premji University)" target="_blank">
Webinar: Ramrao - The Story of India's Farm Crisis...</a>
</li>
<li>
<a href="https://im4change.in/video/water-and-agricultural-transformation-in-India"
title="Water and Agricultural Transformation in India: A Symbiotic Relationship (Source: IGIDR)" target="_blank">
Water and Agricultural Transformation in India: A Symbiotic Relationship...</a>
</li>
<li class="CatArchalLi1">
<a href="https://im4change.in/videogallery"
class="more-link CatArchalAnch1" target="_blank">
More...
</a>
</li>
</ul>
</div>
</div>
</div>
</div>
</section> </div>
<div class="clear"></div>
<!-- Footer option Starts here -->
<div class="footer-bottom fade-in animated4">
<div class="container">
<div class="social-icons icon_flat">
<p class="SocialMargTop"> Website Developed by <a target="_blank" title="Web Development"
class="wot right"
href="http://www.ravinderkhurana.com/" rel="nofollow">
RAVINDErkHURANA.com</a></p>
</div>
<div class="alignleft">
<a
target="_blank" href="https://im4change.in/objectives-8.html"
class="link"
title="Objectives">Objectives</a> | <a
target="_blank" href="https://im4change.in/about-us-9.html"
class="link" title="About Us">About Us</a> | <a
target="_blank" href="https://im4change.in/media-workshops.php"
class="ucwords">Workshops</a> | <a
target="_blank" href="https://im4change.in/disclaimer/disclaimer-149.html"
title="Disclaimer">Disclaimer</a> </div>
</div>
</div>
<!-- Footer option ends here -->
</div>
<div id="connect">
<a target="_blank"
href="http://www.facebook.com/sharer.php?u=https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575.html"
title="Share on Facebook">
<img src="https://im4change.in/images/Facebook.png?1582080640" alt="share on Facebook" class="ImgBorder"/>
</a><br/>
<a target="_blank"
href="http://twitter.com/share?text=Im4change&url=https://im4change.in/latest-news-updates/western-warnings-r-ramachandran-14575.html"
title="Share on Twitter">
<img src="https://im4change.in/images/twitter.png?1582080632" alt="Twitter" class="ImgBorder"/> </a>
<br/>
<a href="/feeds" title="RSS Feed" target="_blank">
<img src="https://im4change.in/images/rss.png?1582080632" alt="RSS" class="ImgBorder"/>
</a>
<br/>
<a class="feedback-link" id="feedbackFormLink" href="#">
<img src="https://im4change.in/images/feedback.png?1582080630" alt="Feedback" class="ImgBorder"/>
</a> <br/>
<a href="javascript:function iprl5(){var d=document,z=d.createElement('scr'+'ipt'),b=d.body,l=d.location;try{if(!b)throw(0);d.title='(Saving...) '+d.title;z.setAttribute('src',l.protocol+'//www.instapaper.com/j/WKrH3R7ORD5p?u='+encodeURIComponent(l.href)+'&t='+(new Date().getTime()));b.appendChild(z);}catch(e){alert('Please wait until the page has loaded.');}}iprl5();void(0)"
class="bookmarklet" onclick="return explain_bookmarklet();">
<img src="https://im4change.in/images/read-it-later.png?1582080632" alt="Read Later" class="ImgBorder"/> </a>
</div>
<!-- Feedback form Starts here -->
<div id="feedbackForm" class="overlay_form" class="ImgBorder">
<h2>Contact Form</h2>
<div id="contactform1">
<div id="formleft">
<form id="submitform" action="/contactus.php" method="post">
<input type="hidden" name="submitform" value="submitform"/>
<input type="hidden" name="salt_key" value="a0e0f2c6a0644a70e57ad2c96829709a"/>
<input type="hidden" name="ref" value="feedback"/>
<fieldset>
<label>Name :</label>
<input type="text" name="name" class="tbox" required/>
</fieldset>
<fieldset>
<label>Email :</label>
<input type="text" name="email" class="tbox" required/>
</fieldset>
<fieldset>
<label>Message :</label>
<textarea rows="5" cols="20" name="message" required></textarea>
</fieldset>
<fieldset>
Please enter security code
<div class="clear"></div>
<input type="text" name="vrcode" class="tbox"/>
</fieldset>
<fieldset>
<input type="submit" class="button" value="Submit"/>
<a href="#" id="closefeedbakcformLink">Close</a>
</fieldset>
</form>
</div>
<div class="clearfix"></div>
</div>
</div>
<div id="donate_popup" class="modal" style="max-width: 800px;">
<table width="100%" border="1">
<tr>
<td colspan="2" align="center">
<b>Support im4change</b>
</td>
</tr>
<tr>
<td width="25%" valign="middle">
<img src="https://im4change.in/images/logo2.jpg?1582080632" alt="" width="100%"/> </td>
<td style="padding-left:10px;padding-top:10px;">
<form action="https://im4change.in/donate" method="get">
<table width="100%" cellpadding="2" cellspacing="2">
<tr>
<td width="33%" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
10
</td>
<td width="33%" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
100
</td>
<td width="33%" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
1000
</td>
</tr>
<tr>
<td colspan="3">
</td>
</tr>
<tr>
<td style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
50
</td>
<td style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
500
</td>
<td style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
<input type="text" name="price" placeholder="?" style="font-family: 'Script Font', cursive, Arial;font-size: 20px;font-weight: 700;">
</td>
</tr>
<tr>
<td colspan="3">
</td>
</tr>
<tr>
<td colspan="3" align="right">
<input type="button" name="Pay" value="Pay"
style="width: 200px;background-color: rgb(205, 35, 36);color: #ffffff;"/>
</td>
</tr>
</table>
</form>
</td>
</tr>
</table>
</div><script type='text/javascript'>
/* <![CDATA[ */
var tievar = {'go_to': 'Go to...'};
/* ]]> */
</script>
<script src="/js/tie-scripts.js?1575549704"></script><script src="/js/bootstrap.js?1575549704"></script><script src="/js/jquery.modal.min.js?1578284310"></script><script>
$(document).ready(function() {
// tell the autocomplete function to get its data from our php script
$('#s').autocomplete({
source: "/autocomplete"
});
});
</script>
<script src="/vj-main-sw-register.js" async></script>
<script>function init(){var imgDefer=document.getElementsByTagName('img');for(var i=0;i<imgDefer.length;i++){if(imgDefer[i].getAttribute('data-src')){imgDefer[i].setAttribute('src',imgDefer[i].getAttribute('data-src'))}}}
window.onload=init;</script>
</body>
</html>'
}
$cookies = []
$values = [
(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39
LATEST NEWS UPDATES | Western warnings-R Ramachandran
Published on Apr 20, 2012
Modified on Apr 20, 2012
India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines.
AS was only to be expected, the two landmark decisions made by the Indian patent office in recent times concerning pharmaceutical patent cases have not gone down well with the multinational drug industry. First, there was the rejection in 2006 of the patent application by the Swiss multinational Novartis for imatinib mesylate (sold under the brand name of Glivec, or Gleevec), its incrementally modified drug for leukaemia, or blood cancer. Then, on March 12, 2012, the Indian generic drug company Natco Pharma Ltd was granted a manufacturing licence to produce a generic version of the patented liver and kidney cancer drug sorafenib tosylate of the German multinational company (MNC) Bayer (brand name Nexavar) through the first-ever invocation of the compulsory licence (CL) provision in the Indian Patents Act, 1970 (as amended in 2005). The CL was granted to ensure affordability of the drug to Indian cancer patients. Natco will now produce the drug at a price that will be 97 per cent lower than Bayer's even after paying 6 per cent royalty on net sales to Bayer.
Bayer will most likely appeal against the order. Novartis challenged the patent office's rejection of its patent application first at the Intellectual Property Appellate Board (IPAB) and subsequently in the Madras High Court. Both upheld the Patent Controller's decision and rejected Novartis' appeals against the Indian government. Now the company has appealed to the Supreme Court. The first hearing is slated for July 10. These two cases have demonstrated how flexibilities available in the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement (for patent protection) of the World Trade Organisation (WTO) can be successfully used to serve public health interests in developing countries over the interests of the private monopoly of profit-driven drug MNCs. The flexibilities in the TRIPS Agreement allow governments to decide what type of “innovation” is patentable. The criteria of “novelty”, “inventive step”, and “industrial applicability” are not defined in the agreement and are left for individual governments to determine within existing national legislation and circumstances. These are also, therefore, test cases for the Indian judiciary, and if these orders can be sustained in the face of imminent legal battles, they will serve as important precedents for exploiting the full power of the Indian Patents Act, while conforming to the WTO's intellectual property rights (IPR) regime, to ensure the Indian public access to health care it can afford.
Drug majors around the world, American companies in particular, which have, of course, been watching the Novartis case anxiously for the past five years, have been further jolted by the latest decision on Nexavar. The president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), John Castellani, issued the following statement immediately after India granted the CL for the indigenous production of Nexavar's generic version:
“While India has not routinely issued CLs, PhRMA believes it is not an appropriate tool even if granting CLs may be a legal option.… Legitimate health emergencies that require making exceptions to IPRs can, and should, be accommodated under the international framework, but only after exhausting all other efforts and under extraordinary circumstances…. [O]ne aspect that is particularly troublesome is the contention that ‘working' a patent requires a company to manufacture within India. It is our firm belief that this is fully at odds with India's TRIPS commitments (as well as broader WTO obligations), and distorts what was intended as a public health exception into an industrial policy…. CLs cannot solve India's larger problems regarding access to medicines and health care.”
The PhRMA's contentions are patently wrong as the decision is in full compliance with the Doha “Declaration on the TRIPS Agreement and Public Health” of November 2001 and Article 31 of TRIPS. But the protest was conveyed more brazenly to the Indian government when the visiting United States Commerce Secretary, John Bryson, raised the issue of India granting a CL to Natco in his meeting with Commerce and Industry Minister Anand Sharma on March 25. Bryson apparently said that any dilution of the international patent regime was a cause for deep concern for the U.S. This was clearly an unwarranted remark on the part of the U.S. official because if there was any perceived violation of TRIPS, the correct forum for the U.S. to address the issue was the WTO.
The U.S. has instituted an internal mechanism under its trade policy to deal with what it perceives as trade barriers in its trading-partner countries on the basis of an annual assessment in what is called the “Special 301 Report” by the office of the U.S. Trade Representative (USTR). India has consistently been placed in the “Priority Watch List” of the report. Following the court's rejection of Novartis' appeal in 2009, the 2010 report included a response of the USTR to the Indian decision.
The report said: “The United States continues to urge India to improve its IPR regime by providing stronger protection for patents. One concern in this regard is a provision in India's Patent Law that prohibits patents on certain chemical forms absent a showing of increased efficacy. While the full import of this provision remains unclear, it appears to limit the patentability of potentially beneficial innovations, such as temperature-stable forms of a drug or new means of drug delivery” (emphasis added, throughout).
The wording clearly reflects the U.S.' objection to the Indian patent office not granting a new patent for a new chemical form of a patented drug that the manufacturer claims had increased bioabsorption but for which there was no proven increased therapeutic efficacy. The 2011 report, too, essentially repeated the same objection to the restricted scope of patentability of drugs under the Patents Act. The administration's objection to the Bayer-Nexavar case is bound to be reflected in the 2012 report, given that the PhRMA has already voiced its protest. Drugs are big business around the world for the U.S. industry, and the PhRMA, which acts as the prime lobby group for the U.S. drug industry, naturally has a major influence on the contents of the Special 301 Report.
In its submission to the USTR on the 2012 Special 301 Report, the PhRMA said the following with regard to the patentability criteria exercised by the Indian patent office in the Novartis case: “Some of the standards for patentability in India are not transparent and are inconsistent with the TRIPS Agreement. For example, Section 3(d) of the [Indian] Patents Act… creates additional hurdles to the grant of certain chemical compound patents, and appears to be applied only to pharmaceuticals. Under this provision, salts, esters, ethers, polymorphs, and other derivatives of known substances are presumed to be the same substance as the original chemical and thus not patentable, unless it can be shown that they differ significantly in properties with regard to efficacy. These additional requirements for patentability beyond novelty, commercial applicability and non-obviousness are inconsistent with the TRIPS Agreement.... Article 27 of the TRIPS Agreement provides a non-extendable list of the types of subject matter that can be excluded from patent coverage. This list does not include ‘new forms of known substances lacking enhanced efficacy', as excluded by Section 3(d) of the Indian law.” This argument is misplaced because the rejection is on the grounds of the new drug not meeting the basic criterion of patentability, which is novelty, meaning that it should be a new compound and should involve an inventive step. Novartis was seeking a patent for just the beta crystalline variant of a patented amorphous molecule, claiming merely better bioavailability. Such an incremental modification is not something that involves inventiveness, the court contended.
On the issue of CLs, which is another key issue of concern to the PhRMA, its submission, made in February, a month before the decision on the Bayer case was pronounced, stated: “Domestic companies have started filing CL applications with the Indian patent office, apparently prompted in part by government statements suggesting that CLs may be a means for ensuring availability and affordability of drugs worldwide…. At a minimum, India should ensure that the CL provisions comply with TRIPS by... eliminating price as a trigger to CL.” (Section 84(1) (b) of the Indian Patents Act permits a CL if the patented invention is not available to the public at a “reasonably affordable price”.)
This again is a misplaced objection because a country is free to decide on the reasons for granting a CL as is clear from the Doha Declaration, which says: “Each member has the right to grant compulsory licences and the freedom to determine the grounds upon which such licences are granted; Each member has the right to determine what constitutes a national emergency or other circumstances of extreme urgency, it being understood that public health crises, including those relating to HIV/AIDS, tuberculosis, malaria and other epidemics, can represent a national emergency or other circumstances of extreme urgency.” The patent office exercised the freedom of granting the CL to Natco on the issue of affordability, given that Natco's generic drug will cost Rs.8,800 a month as against Bayer's Rs.2.8 lakh a month and that cancer treatment is lifelong.
Retaliation following the listing of a country on the watch list includes the U.S. initiating dispute settlement mechanisms at international trade forums such as the WTO, elimination of preferential tariff preferences under bilateral trade agreements, if any, and even unilateral trade sanctions against the named country. Bryson's remarks are perhaps a veiled threat of such action against India since there are many such pharmaceutical patent cases pending in Indian courts for which these cases could become precedents, affecting the potentially huge market of American MNCs. Trade policy forum
There exists a bilateral engagement between India and the U.S. under what is called the U.S.-India Trade Policy Forum (TPF) formed in 2005 alongside the various India-U.S. agreements that came into being, including the nuclear deal. The TPF has five focus groups: agriculture, investment, innovation and creativity (IPR), services, and tariff and non-tariff barriers. Under the TPF, a framework for cooperation and trade was signed two years ago.
Although its proposed work plan does not specifically mention IPR, it does include a group focussing on tariff and non-tariff barriers, which is aimed at “promoting policies to expand market access, including adopting transparent, WTO-policies….” It is quite likely that this bilateral forum will begin to be used by the U.S. to bring on pressure on contentious issues concerning IPR.
Interestingly, the scheduled meeting of the TPF has been postponed twice by the U.S. since October, the most recent being the meeting of the Commerce Minister with USTR Ron Kirk in January. According to media reports, this is because of insufficient progress achieved on the various issues, increasing market access to U.S. companies, in particular. Clearly, the U.S. will increase pressure on the IPR issue in the wake of the recent CL decision at the next meeting of the TPF, which has been pushed to mid-2012. The Indian government would do well to guard against that. Health-care activists and IPR experts have voiced similar concern over the proposed India-European Union (E.U.) Free Trade Agreement (FTA).
According to reports, the 27-nation bloc has been pressing India to agree to an IPR regime over and above TRIPS. This demand is related to the area of pharmaceuticals, particularly after the Novartis decision, and this demand in all likelihood will become stronger now. Recently, however, Minister Anand Sharma assured a visiting UNAIDS (Joint United Nations Programme on HIV/AIDS) executive that India would reject efforts to include a “data exclusivity” clause in bilateral agreements and affirmed the Indian government's full commitment to ensure quality generic medicines through compulsory licensing and other TRIPS flexibilities. Notwithstanding this, in a recent article in The Guardian, Philippe Douste-Blazy, U.N. Special Adviser on Innovative Financing for Development, and Denis Broun, Executive Director of Unitaid, an international facility for the purchase of drugs for HIV/AIDS, malaria and tuberculosis hosted by the World Health Organisation in Geneva, wrote: “If stringent patent and border measures are agreed on at the E.U.-India FTA summit, patients in poor countries will no longer have access to cheap generic medicines; India's role as the ‘pharmacy of the South' could well come to an end.”
The U.S. has already begun to exert such pressures and force countries in some other parts of the world into accepting IPR protection standards that are stronger than the TRIPS regime. Under the Trans-Pacific Partnership, a multilateral free trade agreement between the U.S. and the countries of the Asia-Pacific region that seeks to further liberalise these economies, the U.S. intends to broaden the scope of patentability by eroding the flexibility afforded by TRIPS by requesting TPP partner countries to pass new laws and rules that severely limit the ability of each country to define what is “patentable”. The nine countries currently negotiating the TPP are Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the U.S. and Vietnam. Japan and South Korea are intending to join the group shortly.
A leaked draft of the chapter on IPR in a U.S.-negotiating TPP text, which reflects the U.S. position on this multilateral arrangement, indicates that the U.S. is demanding aggressive IPR provisions that go beyond what international trade law (under TRIPS) requires: “Each Party,” says the draft U.S. proposal, “ shall confirm that: patents shall be available for any new forms, uses, or methods of using a known product; and a new form, use, or method of using a known product may satisfy the criteria for patentability, even if such invention does not result in the enhancement of the known efficacy of that product.” This is the “patent evergreening” technique that Novartis tried to employ, which the Indian patent office rejected. Evergreening of a patent allows pharmaceutical companies to obtain or extend monopoly protection for old drugs simply by making minor modifications to existing formulae. The international organisation Medecins Sans Frontieres (Doctors Without Borders), which provides affordable health care around the world, points out: “Evergreening significantly delays the arrival of more affordable generic medicines into the market.” The TPP draft text further wants plants and animals and diagnostic, therapeutic and surgical methods for the treatment of humans or animals, which are explicitly ruled by TRIPS to be non-patentable, to be patentable.
In addition, another leaked document pertaining to the TPP seeks to eliminate the process of pre-grant opposition to a patent application, which is an important tool to prevent patent applications based on weak or erroneous information. The U.S. proposal, if accepted, would allow opposition only after the patent is granted.
Although this does not directly or immediately affect the Indian situation, it does portend ominous moves on this front by the U.S. on India as well. This is evident from the remarks Ron Kirk made recently: “U.S. involvement in the TPP is predicated on the expansion of the agreement to include more economies in the Asia-Pacific region…[and] should set the standard for 21st century trade agreements going forward.”
It, therefore, stands to reason that the norms that emerge from the TPP negotiations will serve as the template for future U.S. trade agreements across the world. Using the leverage of the many countries in the TPP fold, and perhaps in other bilateral agreements, which accept this new enlarged premise for patentability, the WTO, too, eventually might come under pressure to change its rules of dispute settlement and arbitration. The implications of this are that IPR regimes, in particular the strict patentability criteria for drugs, of countries such as India, which have the responsibility of extending affordable health care to millions, will increasingly come under severe attack from the U.S. and the E.U., where nearly all the big drug multinationals operate and profit at the cost of the suffering poor of developing countries.
Write Comments